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Abstract
A LONGITUDINAL STUDY OF THE MOTIVATIONS FOR THE NON-MEDICAL USE OF
PRESCRIPTION DRUGS IN A NATIONAL SAMPLE OF YOUNG ADULTS
By: Tess K. Drazdowski, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016.
Major Director: Wendy L. Kliewer, Ph.D., Chair and Professor of Psychology, Department of
Psychology
Young adults are most at-risk for the non-medical use of prescription drugs (NMUPD) and many
of its associated negative consequences. Understanding this population’s motivations for use can
help to inform efforts to reduce NMUPD. Past research has been limited in scope, consisting
primarily of cross-sectional work with college students focusing on prescription stimulants. The
current study researched how motivations for NMUPD changed over young adulthood using
three waves of data from a longitudinal, nationally representative sample of 14,990 19 to 24 year
olds in the Monitoring the Future study cohorts collected between 1976 to 2013. Prescription
stimulants, central nervous system (CNS) depressants, and opioids were investigated, along with
sex and college attendance as potential moderators. Differences in NMUPD motivations for
young adults who initiated NMUPD in high school versus in early young adulthood were
studied. Additionally, motivation patterns of new users were investigated. Analyses indicated
that both recreational and self-treatment motivations commonly were reported over time and
across drug classes, with four to five popular motivations acknowledged in each class. In
general, generalized estimated equations repeated measure analyses found that NMUPD
motivations remained relatively stable across young adulthood, with some reductions for the
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motivations of experimentation and boredom, and an increase in select self-treatment
motivations. Overall, men were more likely to endorse recreational motivations, while women
were more likely to endorse self-treatment motivations, though this varied somewhat by
prescription drug class. Young adults not enrolled in college courses were more likely to endorse
using stimulants non-medically for different reasons than their peers who were enrolled. There
also were differences in motivations based on if young adults initiated NMUPD in high school
compared to when they were 19/20 years old. However, motivations were fairly consistent across
young adult development regardless of when NMUPD was initiated. These data suggest that
efforts aimed at preventing or reducing NMUPD in young adult populations should include
targets to reduce both self-treatment and recreational motivations; may need to be tailored by
prescription drug class, sex, and college attendance status; could start in high school; and can be
used for new and continued users across young adulthood.

A Longitudinal Study of the Motivations for the Non-medical Use of Prescription Drugs
in a National Sample of Young Adults
Statement of the Problem
The non-medical use of prescription drugs (NMUPD) is a significant and growing public
health concern with young adults at great risk for use, abuse, and related negative outcomes (e.g.,
National Institute on Drug Abuse (NIDA), 2011). According to NIDA, NMUPD occurs when
individuals either use medications that were not prescribed to them, use their prescribed
medications in higher quantities or manners other than prescribed, or take medications for
purposes other than prescribed (e.g., to get high; NIDA, 2014). The types of prescription drugs
used for non-medical purposes most often are stimulants, opioids, and central nervous system
(CNS) depressants (NIDA, 2011).
As a population characterized by instability and experimentation, young adults (ages 1825) are clearly an at-risk group for substance use (Arnett, 2005). It is during young adulthood
that, on average, people report initiation of illicit substance use, including NMUPD (Substance
Abuse and Mental Health Services Administration (SAMHSA), 2013b). Young adults exhibit the
greatest illicit drug use compared to all other age groups in the United States (SAMHSA, 2013b).
Additionally, within the twenties is the mean age for onset of NMUPD disorders, and for seeking
treatment for these disorders (Huang et al., 2006). Further, evidence suggests that adolescent
decision-making is different than that of young adults, which is different from older adults, as a
result of brain development (for a reviews see Spear, 2013; Steinberg, 2008). Consequently the
motivations to engage in NMUPD, and the interventions targeting NMUPD, will likely vary by
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age. Therefore, this study focuses on the developmental period of young adulthood, the
population considered most at-risk.
NMUPD is the second most commonly reported form of illicit substance use by young
adults, after marijuana (SAMHSA, 2013b). This is a growing public health concern. For example
in 2014, 884,000 young adults engaged in NMUPD for the first time in the past year (Lipari et
al., 2015). In full-time college students (ages 18 to 22), NMUPD initiation peaked with an
average of 850 new users per day for prescription opioids alone in 2013 (Lipari, 2015). More
people also have been seeking treatment for prescription opioid abuse, with rates for young
adults increasing by approximately 26% from 2002 to 2010 (SAMHSA, 2011).
NMUPD has been linked with abuse and dependence (Huang et al., 2006; Hurwitz, 2005;
Kroutil et al., 2006; SAMHSA, 2013b), and a variety of other negative outcomes in young
adults, including mental illness (Arria et al., 2008; Bavarian et al., 2013; Janusis & Weyandt,
2010; Lo et al., 2013; McCauley et al., 2009; McCauley et al., 2010; McCauley et al., 2011; Van
Eck et al., 2012; Zullig & Divin, 2012), increasing number of emergency room visits (SAMHSA,
2013a; SAMHSA, 2013b), arrest and delinquency (Drazdowski et al., 2015; Herman-Stahl et al.,
2007), and more unintentional overdose deaths (Paulozzi, 2012). Additionally, young adults who
engage in NMUPD are significantly more likely than their peers to use other illicit drugs and to
combine prescription drugs with alcohol and other substances, which increases the risk of
potentially dangerous drug interactions and their negative outcomes (Garnier et al., 2009;
McCabe et al., 2006; SAMHSA, 2006). Of particular concern for young adults in collegiate
settings, many students who endorsed the non-medical use of prescription stimulants and opioids
also reported spending less time studying, skipping classes more often, earning lower grades
(Arria et al., 2008), more frequent sexual risk behaviors (Benotsch, Koester, Luckman, Martin, &
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Cejka, 2011), and more sleep problems (Clegg-Kraynok, McBean, & Montgomery-Downs,
2011). Clearly NMUPD, particularly by young adults, is a large and growing public health
problem with significant consequences. Therefore, prevention is key to reducing this public
health concern and its grave costs to society.
Unfortunately, the majority of individuals with NMUPD disorders never receive
treatment for their drug use problems or any mental health issues (Huang et al., 2006). One way
to prevent substance use is to investigate why specific groups of people use and to target
interventions specifically to certain predictors. One of these factors, on the individual level, is the
motivations for why young adults decide to engage in NMUPD. Although it is only one small
piece of the etiology for drug use and abuse, and needs to be considered along with other factors
such as molecular genetics, personality patterns, culture, etc. (see Kendler, 2012); motivations
can be self-reported and are amendable to change (e.g., Miller et al., 1993).
Different theories exist to explain why individuals are motivated to abuse substances.
One theory is the self-medication hypothesis initially articulated by Khantzian (1985; 1997) and
Duncan (1974a; 1974b; 1975). This theory posits that individuals engage in drug abuse to treat
underlying disorders or problems that have not been properly treated by other means. For others,
initial use may have started appropriately, such as for pain or for sleep, but then developed into
addictions based on the properties of the medications themselves (Alam et al., 2012). More
common in young adults is the theory that individuals ages 18 to 25 are motivated to engage in
drug use for recreational reasons, partially as the result of the instability and exploration
encompassing that developmental life stage (Arnett, 2005).
Previous research supports that motivations for substance use are important predictors of
use patterns and problems in young adults. For example, drinking motivations predict alcohol

3

consumption and alcohol-related problems in young adults and adolescents (Kuntsche et al.,
2005), as well as mediate or moderate environmental and individual variables with alcoholrelated outcomes in these populations (Cooper et al., 2000; Magid et al., 2007; Kuntsche et al.,
2010; Kenney et al., 2014). Research investigating motivations in young adults supports that
similar patterns exists for NMUPD. For example, college students who use prescription drugs
recreationally are more likely to endorse using other drugs, binge drinking, and combining their
prescription drugs with other substances (Advokat, Guidry, & Martino, 2008; Barrett, Darredeau,
Bordy, & Pihl, 2005; McCabe, Cranford, Boyd, & Teter, 2007; McCabe, Boyd, & Teter, 2009).
Although, in at least one study there were no significant differences in lifetime number of drugs
used between students who used stimulants recreationally versus as a study aid (Barrett et al.,
2005). Additionally, in another study, recreational users also were more likely to report using
treatment services for substance use compared to users who engaged in NMUPD for selftreatment reasons. Unfortunately, the frequency for using treatment services was still small
(10.3%; McCabe et al., 2009). Also, students motivated to use prescription stimulants for
recreational reasons were more likely to report intranasal use than those using it as a study aid; a
risk factor for drug abuse (Franke et al., 2011). Clearly, motives are important, not just in how
they related to NMUPD, but also how they relate to other risk behaviors.
Since different motivations relate to different patterns of use and outcomes, prevention
and intervention efforts will likely need to be targeted to most effectively address the
individual’s needs based on their specific motivations for use. For instance, an individual
reporting addiction as a motive may need different treatment than an individual reporting
recreational motives, like to have fun. Additionally, motivations have been recognized by
SAMHSA as an important treatment target (Center for Substance Abuse Treatment, 2013).
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The research conducted on the motivations for NMUPD in young adults to date is limited
in several important ways. The majority of the work has surveyed students in higher education,
with little work considering how motivations may be similar or different among young adults
who are not attending college. Additionally, the preponderance of research is about the nonmedical use of prescription stimulants. Very few studies have focused on other commonly
abused prescription drug classes like prescription opioids and CNS depressants (National
Institute on Drug Abuse (NIDA), 2011). Further, only one longitudinal study has been conducted
looking at motivations over time in this population (Garnier-Dykstra, Caldeira, Vincent,
O'Grady, & Arria, 2012). However, Garnier-Dykstra and colleagues (2012) focused only on
college students who non-medically used prescription stimulants. McCabe, Schulenberg,
O'Malley, Patrick, and Kloska (2014) did investigate trends in the non-medical use of
prescription opioids during young adulthood in a national sample, but did not include
motivations in the analyses. Without longitudinal work, it is unclear exactly how motivations for
NMUPD may change over time and if the same motivations continue to influence individuals as
they progress developmentally.
Therefore, the current study contributes to the literature on the motivations for NMUPD
in young adults by addressing some of the limitations of past work. First, the sample consisted of
a nationally representative sample of high school seniors who have been followed longitudinally
across three biennial follow-up waves covering ages 19-24 years. With this sample, questions
about how motivations for NMUPD change over time on the national population level were
answered. Also, if there are differences over time for motivations for NMUPD of young adults
who attend college as compared to their peers who do not were investigated, as well as sex
differences. Further, motivations for new users in the beginning of young adulthood, compared
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to those who used in high school, as well as changes in NUMPD motivations for new users over
time were studied. Specific motivations for the non-medical use of prescription stimulants, CNS
depressants, and opioids were investigated. Thus, expanding the knowledge on less studied
prescription drug classes. The strengths of the current study move the research on the topic of
motivations for NMUPD forward.
Review of the Literature
Definition and Prevalence of NMUPD in Young Adults
As noted, NMUPD occurs when individuals either use medications that were not
prescribed to them, use their prescribed medications in higher quantities or manners other than
prescribed, or take medications for purposes other than prescribed (e.g., to get high; NIDA,
2014). Rates of NMUPD vary across prescription drug class and sample. For example, estimates
from recent nationally representative databases suggest prevalence rates from 3.3% to 4.8% in
young adults (SAMHSA, 2014). However, studies in U.S. college student samples report ranges
from 4% to 43% (Advokat et al., 2008; Stone & Merlo, 2011). The types of prescription drugs
abused most often are stimulants, CNS depressants, and opioids (NIDA, 2011).
Stimulants are commonly prescribed for Attention-Deficit/Hyperactivity Disorder
(ADHD), the sleep disorder narcolepsy, and obesity (NIDA, 2011; Yu, 2012). Prescription trends
suggest that the number of methylphenidate prescriptions (e.g., Concerta, Ritalin) have remained
relatively stable since 1996 (NIDA, 2011), but the rates of amphetamine prescriptions (e.g.,
Adderall, Dexedrine) have increased (Califano, 2005); with a reported 463% increase between
1998 and 2007 alone (Belouin, Reuter, Borders-Hemphill, & Mehta, 2008). These medications
typically are abused because of their ability to increase alertness and attention (Yu, 2012). As
stimulants tend to increase heart rate and blood pressure, they have been associated with sudden
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death (Gould et al., 2009). However, it should be noted that two large studies have provided
evidence that stimulants do not increase the risk of negative cardiovascular events (Cooper et al.,
2011; Habel et al., 2011). That being said, the risk of adverse cardiovascular events still exists
for individuals in the abuse setting who are taking large dosages (Yu, 2012). Tolerance for these
medications develops over time, resulting in individuals needing higher doses, or more potent
drugs to achieve the “high,” similar to other illicit drugs like cocaine and D-amphetamine (i.e.,
“speed”; Rosenfield, Hébert, Stanbrook, Flegel, & MacDonald, 2011).
CNS depressants often are referred to as tranquilizers or sedatives. They include
barbiturates, benzodiazepines, and nonbenzodiazepine sleep medications (Yu, 2012). These
medications commonly are prescribed for anxiety or sleep problems as they slow normal brain
function. Specifically, barbiturates are used to treat sleep and anxiety disorders (Yu, 2012).
Benzodiazepines treat anxiety disorders, insomnia, panic disorders, seizures, and muscle
spasticity (Lalive, Rudolph, Luscher, & Tan, 2011). Nonbenzodiazepines hypnotics, also known
as “Z-drugs,” are designed to aid sleeping and be less likely to produce tolerance or dependence
problems (Nutt & Stahl, 2010). Prescribing trends provide evidence that there has been a
significant reduction in barbiturate prescriptions; however, this is counter-balanced with an
increase in all other CNS depressant medications (Califano, 2005). These medications are abused
because of their ability to reduce anxious feelings and inhibitions, similar to the reported
euphoric effects of alcohol (Yu, 2012). Withdrawal symptoms include insomnia, tremors,
agitation, anxiety, gastric problems and muscle spasms, which can lead to physical dependence
(Lalive et al., 2011). The prevalence of lifetime use of CNS depressants among young adults for
benzodiazepines only was estimated to be about 13% in 2013 (Johnston, O’Malley, Bachman,
Schulenberg, & Miech, 2014).
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Opioids are prescribed primarily for pain relief (U.S. Food and Drug Administration,
2014). These medications also can be prescribed as antitussive or antidiarrheal agents (Yu,
2012). Trends in prescribing suggest that opioids are being used increasingly to treat chronic
pain, acute and postsurgical pain, as well as for palliative care (Manchikanti, Fellows, Ailinani,
& Pampati, 2010). This trend is the most noticeable in the U.S., as the U.S. alone consumes
around 80% of the world’s supply of opioids even though residents only make up 4.6% of the
world’s population (Manchikanti et al., 2010). Prescription opioids are commonly abused
because of their ability to induce a feeling of euphoria. Abuse of prescription opioids also leads
to tolerance for these medications (NIDA, 2011). Undesirable withdrawal symptoms, such as
sleep problems, anxiety, chills, runny nose, sweating, muscle twitching, muscle aches, and
agitation, also encourage users to continue to use these medications (SAMHSA, 2013c). Among
young adults, the prevalence of the non-medical use of prescription opioids has remained
relatively stable since 2002, with a recent decline according to the National Survey on Drug Use
and Health (NSDUH), ranging from 20.8% (2013) to 25.5% (2005-06). A similar trend was
reported in the Monitoring the Future (MTF) study, with prevalence rates for young adults
ranging from 14.5% (2013) to 17.9% (2006; SAMHSA, 2014).
Rates of overall NMUPD are rising and young adults are at more risk than other age
group. For example, in 2010 there was an average of 6,600 new NMUPD initiates per day
(SAMHSA, 2013b). There were approximately 1.4 million new users of tranquilizers and
sedatives. From 2002 to 2010, the rate of just opioid dependence increased from 0.4% to 0.6% of
the population, resulting in an increase from 936,000 to 1,400,000 people with about one third
aged 18 to 25 (SAMHSA, 2011). More people have also been seeking treatment for opioid
abuse; with the rates for young adults increasing by approximately 26% from 2002 to 2010.
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Additionally, the early 20s is the mean age for onset of NMUPD disorders across types of
prescription medication, and the mid-20s is the mean age for seeking treatment for NMUPD
disorders (Huang et al., 2006). Therefore, young adults are an important population to target for
prevention and intervention.
There are a variety of reasons for why NMUPD is becoming more common, especially
with young adult populations. First, there has been an increase in retail sales of prescription
medications that has led to more availability (Yu, 2012). Specifically, between 1997 and 2007,
the retail sales of opioids more than doubled, with 126.5 million grams sold in 2007
(Manchikanti et al., 2010). From 1991 to 2010, the total number of opioid prescriptions increased
from 76 million to 210 million (NIDA, 2011). Another factor implicated in the increasing rates
of NMUPD is the perception that because they are prescribed, and thus approved by Federal
Drug Administration (FDA), they are “safer” than other drugs. Many studies have found that
young adults believe this to be true (Arria, Caldeira, Vincent, O'Grady, & Wish, 2008; DeSantis,
Webb, & Noar, 2008; Fleary, Heffer, & McKyer, 2013; Inciardi, Surratt, Kurtz, & Cicero, 2007;
Mui, Sales, & Murphy, 2014). Prescription drugs, like prescription opioids, also are perceived as
less stigmatizing and less illegal when compared to other illicit drugs like heroin (Inciardi et al.,
2009). Further, young adults also appear to not be knowledgeable about the illegality of giving or
taking prescription drugs without a doctor’s permission (DeSantis et al., 2008). For these
reasons, it is important to further investigate NMUPD users in this developmental period.
Negative Behaviors and Outcomes Associated with NMUPD in Young Adults
Every prescription medication comes with warnings of potential adverse side effects.
Individuals engaging in NMUPD are putting themselves at-risk for experiencing these negative
effects. For instance, if one takes too many prescription opioids he/she may experience loss of
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muscle tone, confusion, slowness of heart rate, stupor, respiratory depression, coma, and even
sudden death (SAMHSA, 2013c); while overdoses of stimulants can result in seizures, feelings
of paranoia, respiratory failure, or cardiac arrest. Other adverse effects of stimulants include
headache, palpitations, hypertension, arrhythmias, depression, agitation and aggressiveness
(NIDA, 2011). CNS depressant abuse can produce disinhibitory and aggressive effects that result
in violence and assault (Lader, 2011). The risk of experiencing these adverse effects is increased
when prescription drugs are combined or used in combination with other drugs or alcohol. If
CNS depressants are used with alcohol and opioids, the aforementioned problems are more
severe and common (Jann, Kennedy, & Lopez, 2014; Lader, 2011). In another example, CNS
depressants and alcohol are commonly also found in opioid-related deaths in the United States
(Webster et al., 2011). Also, individuals who engage in NMUPD have reported medical
problems such as cardiac arrhythmias and respiratory depression (Nissen, 2006), as well as
cognitive deficits (Barker, Greenwood, Jackson, & Crowe, 2004; Barker, Greenwood, Jackson,
& Crowe, 2004).
Further, medical emergencies related to NMUPD have increased 132% from 2004 to
2011 (SAMHSA, 2013b). Over 1.2 million emergency department (ED) visits involved the nonmedical use of prescription medicines, over-the-counter drugs, or other types of pharmaceuticals
in 2011, accounting for 51% of all ED visits involving illicit substances (SAMHSA, 2013a;
Paulozzi, 2012). Since 2004, rates of suicide cases that involve some type of CNS depressant
have increased between 105% and 148% depending on type of medication (SAMHSA, 2013a).
NMUPD also is involved in the rising numbers of unintentional overdose deaths. From 1999 to
2000, unintentional overdose deaths involving opioid pain relievers alone have quadrupled, and
by 2007 they outnumbered those involving heroin and cocaine combined (Paulozzi, 2012).
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NMUPD also leads to abuse and dependence (Huang et al., 2006; Hurwitz, 2005; Kroutil
et al., 2006; SAMHSA, 2013b) and potentially may be “gateway” drugs for other illicit
substances. Approximately, 54,000 young adults met criteria for NMUPD abuse or dependence
in 2012 (SAMHSA, 2013b), with individuals reporting the most abuse and dependence for
stimulants in the United States, specifically amphetamines (Huang et al., 2006). In samples from
a variety of studies of individuals who inject heroin, 24%-86% reported the misuse of
prescription opioids first, suggesting that NMUPD may be a risk factor for future drug use
(Brands, Blake, Sproule, Gourlay, & Busto, 2004; Cicero, Ellis, Surratt, & Kurtz, 2014; Cicero,
Ellis, & Surratt, 2012; Grau et al., 2007; Lankenau et al., 2012; Peavy et al., 2012; Pollini et al.,
2011).
Young adults who report NMUPD also report more cigarette smoking, heavy episodic
drinking, marijuana use, cocaine use, hallucinogen use, inhalant use, and use of other illicit
substances (Garnier et al., 2009; McCabe et al., 2006; SAMHSA, 2006). These combinations can
increase their risks of negative outcomes. Indeed, more than half of ED visits for prescription
drug abuse involve multiple drugs and approximately 20% also involve alcohol (SAMHSA,
2013b). Further, NMUPD drug use disorders are associated with many other Axis I and II
disorders (Huang et al., 2006). This comorbidity between mental health problems and substance
use puts NMUPD users at even greater risk for negative outcomes. For instance, individuals with
comorbid mental health symptoms who engage in NMUPD are at increased risk of NMUPD
overdoses (Braden et al., 2010; Porucznik, Johnson, Sauer, Crook, & Rolfs, 2011).
Within the general community, NMUPD has become a public safety threat, with
increases in property and violent crime associated with prescription drug diversion (Inciardi et
al., 2007). NMUPD is a predictor for an increased risk of future delinquency in youth already
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involved in the justice system (Drazdowski, Jäggi, Borre, & Kliewer, 2015), although other
known risk factors (e.g., previous delinquency, violence exposure) put youth more at risk than
NMUPD alone. Young adults specifically, from a national sample, also have increased arrest
rates if they report the non-medical use of prescription stimulants (Herman-Stahl, Krebs, Kroutil,
& Heller, 2007).
Of particular concern for young adults in collegiate settings, many students who endorse
the non-medical use of prescription stimulants and opioids spent less time studying, skipped
classes more often, and earned lower grades (Arria et al., 2008). Additionally, NMUPD has been
associated with more frequent sexual risk behaviors in college students (Benotsch, Koester,
Luckman, Martin, & Cejka, 2011). They also report more sleep problems (Clegg-Kraynok,
McBean, & Montgomery-Downs, 2011). Further, depression has been associated with NMUPD
in college students (Bavarian, Flay, & Smit, 2014; McCauley et al., 2011; Zullig & Divin, 2012).
Similar results have been found for the relation between ADHD symptoms and the non-medical
use of prescription stimulants in college students (Arria et al., 2011; Janusis & Weyandt, 2010;
Van Eck et al., 2012). There is a wealth of evidence that NMUPD, particularly by young adults,
is a large and growing public health problem with significant consequences.
Developmental Stage of Young Adulthood
The international chronological age for defining adulthood is 18 years old (Cohen,
Stromquist, Behrman, & Lloyd, 2006). However, in today’s society in the United States the
traditional transitional markers that have defined adulthood, such as marriage and having
children, are no longer the most prominent markers characterizing young adults (e.g., Settersten,
Furstenberg, & Rumbaut, 2005). Scholars are recognizing that there is a separate developmental
period between adolescence and adulthood. This new transitional time in development is

12

occurring across cultures in industrialized nations. For example, in Japan, “freeters” are
individuals aged 15 to 34 who typically are working part-time, temporary positions and are not
enrolled in higher education (Newman, 2008). In the United States the popular press has referred
to individuals in this developmental stage as “twixters” (Grossman, 2005), or used the term
“adultscence” (Gordon & Shaffer, 2004). These terms highlight a more recently recognized inbetween developmental stage of young adulthood where more self-exploration occurs after
adolescence and the stability and maturity of adulthood is not yet achieved. During this period
some of the following social role transitions are expected to occur: leaving home, gaining
financial independence, gaining independence in decision making, making a partnership
commitment, renegotiating relationships with parents, starting a career, becoming a parent,
engaging with the community and the wider social world (Hutchison, 2015).
More research has been conducted about the development of the brain during this life
stage and have found that brain development does not cease in adolescence (see Casey & Jones,
2010; Crews, He, & Hodge, 2007; Gladwin, Figner, Crone, & Wiers, 2011; Spear, 2013;
Steinberg, 2008 for reviews). Rather, researchers have found that in young adulthood the brain is
still developing and a neurologic pruning process occurs which leads to more focused and
efficient processing in the later adult years. Gray and white matter continue to increase into the
early 20s. Additionally, brain areas responsible for emotions (e.g., amygdala) become fully
developed by mid-adolescence while the frontal lobes are still in development. Research has now
found evidence that the frontal lobes do not reach maturity until approximately age 25. As the
frontal lobes are responsible for long-term thinking, it is more common to see emotion-driven
decision-making as compared to methodical decision-making during this stage. Accordingly,
there are increases in risk-taking with young adults being less likely to regard possible
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consequences. Further, there is an increased susceptibility during this stage to the rewarding
properties of substances as compared to older adults.
Which biological ages define young adulthood is debated by developmental
psychologists and scholars. For example, suggested age ranges have included 17 to 45
(Levinson, 1986), 18 to 34 (Settersten et al., 2005), and 22 to 34 (Ashford & LeCroy, 2010).
However, some theorists have found these age ranges too broadly defined. Specifically, Arnett
(2000) states, “It makes little sense to lump late teens, twenties, and thirties together and call the
entire period young adulthood. The period from ages 18 to 25 could hardly be more distinct from
the thirties.” (p. 479).
Theory of emerging adulthood. Jeffery Arnett has specifically defined the term
“emerging adulthood,” to capture the distinct development stage between adolescence and
adulthood that occurs between ages 18 to 25 in industrialized societies (Arnett, 2000). This age
stage is based on research suggesting that the majority of young adults ages 18 to 25 do not
believe that they have reached adulthood yet; but by age 30 most people believe they have
reached adulthood. The central focus of emerging adulthood is a prolonged identity exploration
(Arnett, 2007; Arnett, 2006). Specifically, during this stage young adults are exploring social and
economic roles by experimenting with new experiences related to love, work, financial
responsibilities, and educational interests, without committing to a particular long-term plan.
Arnett conceptualizes this as a period of unstructured time where emerging adults are not yet
attached to social institutions (Arnett, 2007). For instance, young adults in this stage are moving
out from their families of origin and have not formed new families of their own yet. The mid-20s
is when residential instability and mobility are typically at their highest (Rindfuss, Cooksey, &
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Sutterlin, 1999). Additionally, many are moving out from prior educational systems into new
educational or employment sectors.
As a result of all these changes, this developmental period is marked by experimentation
and instability. Therefore, it is not surprising that it also is during the ages of 18 to 25 that we
find the most reported illicit drug use (SAMHSA, 2013b). Further, between the ages of 18 to 25
are when many individuals are at-risk for developing mental health disorders. Beyond being at
the most risk for NMUPD abuse and dependence (Huang et al., 2006), young adults also are atrisk for the onset of many other disorders such as depression, generalized anxiety, schizophrenia,
and bi-polar disorder to name a few (Kessler et al., 2005).
Theories of Motivations for Substance Abuse in Young Adults
There are many theoretical frameworks for the motivations behind initial drug use and
continuing drug abuse. One theory for why individuals are motivated to use and abuse drugs is
the psychodynamic and behaviorally self-medication hypothesis initially articulated by
Khantzian (1985; 1997) and Duncan (1974a; 1974b; 1975). This theory posits that individuals
engage in drug abuse to treat underlying disorders or problems that have not been properly
treated by other means. Self-medication occurs because individuals self-diagnosis their
symptoms or problems and seek means to alleviate these symptoms. As a result, individuals
chose to use or abuse certain substances based on their specific symptoms. For example, an
individual who has self-diagnosed attention problems may self-medicate with prescription
stimulants, while a person with anxiety and sleep problems would instead self-medicate with
CNS depressants. Further, this theory highlights the negative reinforcement experienced by drug
users. Users who self-medicate are motivated to reduce their symptoms and negative affect, as
well as to avoid withdrawal symptoms. These experiences reinforce future use of drugs. This
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theory is supported by findings that one factor that differentiates recreational users from
problematic users is the presence of negative reinforcement. If the presence of negative
reinforcement is reported, individuals are more likely to be problematic users (Nicholson,
Duncan, & White, 2002). The self-medication hypothesis would support motivations where
individuals are using prescription drugs non-medically as they were intended (e.g., stimulants to
improve concentration). Additionally, this theory would support motivations that suggest
escaping stressors and problems (e.g., to get away from my problems or troubles).
However, the self-medication hypothesis does not appear to account for all young adults
who use prescription drugs non-medically. For others, initial prescription drug use may have
started appropriately, such as with a prescription for pain or for sleep from a doctor, but then
developed into addictions based on the properties of the medications themselves. For example,
studies have shown that patients are more likely to become long-term opioid users if they were
prescribed with an opioid within seven days of surgery, compared with those who received no
opioid prescription (Alam et al., 2012). As all of the prescription drugs that are commonly
abused have some addictive properties with the development of tolerance and associated
withdrawal symptoms, as noted earlier, this theory of substance use and abuse also may be
occurring and needs to be considered as a potential motivation (e.g., because I am “hooked”—I
feel I have to have them).
Additionally, more common in young adults is the theory that individuals ages 18 to 25
engage in more drug use for recreational reasons as part of the self-exploration process and
instability experienced during this this developmental period (Arnett, 2005). Specifically Arnett
(2005) suggests that emerging adults use substances because they are curious about the
experiences of using various substances and want to have a wide range of experiences before
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they settle into adult life. Also, since constructing a stable identity may be confusing and
difficult, emerging adults may use substances to relieve these negative feelings stemming from
identity confusion. Further, as emerging adulthood is a time of instability; young adults may be
more likely to use substances because of the stress and negative affect that are associated with
disruptions in life (e.g., new residences, romantic partners, educational and vocational settings).
Young adults also have the ability to make more independent decisions, and are
frequently transitioning out of their parents’ house which may lead to engaging in more deviant
behaviors including substance use. Substance use also may be explained by the feeling of inbetween experienced by many young adults; that they are no longer adolescents but not yet
adults. Therefore, young adults have the ability to make independent choices about substance use
that their caregivers previously had decided against, however, they do not yet feel the need to be
as responsible in their drug use as they believe adults should act. This part of Arnett’s theory also
is supported by research on brain development suggesting that young adults do not yet have the
cognitive capacity to make methodical decisions over emotion-driven decisions (e.g., Steinberg,
2008).
Finally, Arnett (2005) proposes that emerging adulthood sets individuals up for believing
that they have the opportunity to make dramatic changes in their lives and optimism is very
common. As a result of this optimism people in this developmental stage may not fully consider
the negative consequences that may result from substance use. All of these potential explanations
may relate to different motivations to engage in NMUPD, especially recreational motives (e.g.,
to experiment—to see what it’s like, to feel good or get high, to seek deeper insights and
understanding, to have a good time with my friends, to fit in with a group I like, because of
boredom/nothing else to do, etc.).
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For the purposes of this study the focus point for prevention and intervention will be on
the individual level and one’s reported motives to use. Although it is only one small piece of the
etiology for drug abuse and needs to be considered along with other factors such as molecular
genetics, personality patterns, culture, etc. (see Kendler, 2012), motivations are a factor that can
be self-reported and are amendable to change (e.g., Miller, Benefield, & Tonigan, 1993). Since
different motivations relate to different theories of drug abuse, prevention and intervention
efforts will likely need to be targeted to most effectively address the individual’s needs based on
their specific motivations for use. For instance, an individual reporting addiction as a motive may
need different treatment than an individual reporting recreational motives. Motivations have been
recognized by SAMHSA as an importance treatment target. This is highlighted in their
publication, “Enhancing Motivation for Change in Substance Abuse Treatment,” a 260-page
document that is part of their Treatment Improvement Protocol (TIP) Series (Center for
Substance Abuse Treatment, 2013).
Furthermore, given the theory of instability in this life stage (Arnett, 2005), there may be
changes in the patterns of motivations reported by young adults across this period. Research is
needed on this topic to help determine where to target interventions to make them
developmentally appropriate. Hopefully research in this area will help reduce the findings that
the majority of individuals with NMUPD disorders never received treatment for their drug use
problems or any mental health issues (Huang et al., 2006).
Research on Motivations for NMUPD in Young Adults
With the high rates of use and the associated negative outcomes from use, research on the
motivations for NMUPD in young adults has been a burgeoning area. The following section
describes the research on motivations for NMUPD in exclusively young adults to date. The
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description of the studies is organized by class of prescription medication investigated as defined
by NIDA: stimulants, opioids, and CNS depressants so summaries of the general trends in
motivations can be described. Then, research that included young adults not currently enrolled in
college will be discussed to address any differences found in this population. If sex differences
have been reported in any studies they also are presented. Finally, results that include work
outside of the United States, but still conducted in industrialized nations, will be reviewed as a
comparison for motives across cultures. After reviewing the results of the separate drug classes
research that has investigated motives across drug classes (i.e., NMUPD in general) will be
discussed to acknowledge general trends in NMUPD.
Overall, the majority of the studies investigated the motivations to use stimulants nonmedically; followed by studies investigating prescription opioids and CNS depressants,
respectively, either as a separate study or along with investigating the motives for the nonmedical use of stimulant mediations. Across class of prescription medication, the majority of the
research was conducted in the United States with college students and was cross-sectional.
Motivations for the non-medical use of stimulants. Thirty-five studies have
investigated the motivations for the non-medical use of prescription stimulants in young adult
populations exclusively. Of these articles, 31 were conducted in the United States and four were
conducted outside of the United States. Additionally, all articles included college student
samples, while two included other young adult populations. Sample sizes ranged from 50 to
9,161 young adults.
Stimulant motivation results in United States samples. Overall, in all but three studies,
the common motivations for stimulant non-medical use were to use the medications for academic
reasons and for reason the medications are clinically prescribed (e.g., to improve concentration;
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Advokat et al., 2008; Barrett et al., 2005; Bavarian et al., 2013; Clegg-Kraynok et al., 2011;
DeSantis et al., 2008; Dupont, Coleman, Bucher, & Wilford, 2008; Dussault & Weyandt, 2013;
Franke et al., 2011; Gallucci, Usdan, Martin, & Bolland, 2014; Garnier-Dykstra et al., 2012;
Ghandour, El Sayed, & Martins, 2012; Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005;
Hartung et al., 2013; Herman et al., 2011; Holloway & Bennett, 2012; Judson & Langdon, 2009;
Lookatch, Dunne, & Katz, 2012; Lord et al., 2009; Low & Gendaszek, 2002; McCabe et al.,
2009; McNiel et al., 2011; Peterkin, Crone, Sheridan, & Wise, 2011; Prudhomme White, BeckerBlease, & Grace-Bishop, 2006; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, &
Swartzwelder, 2009a; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & Swartzwelder,
2009b; Rozenbroek & Rothstein, 2011; Rozenbroek & Rothstein, 2011; Stone & Merlo, 2011;
Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; Teter, McCabe, LaGrange, Cranford, & Boyd,
2006; Tuttle, Scheurich, & Ranseen, 2010; Upadhyay et al., 2010; Weyandt et al., 2009).
Even though the main motivations were to use prescription stimulants for academic
reasons or for the drugs prescribed effects, recreational motives also were common. For example,
across studies the motivation to get high was reported in 2% to 43% when it was recorded in the
sample (Gallucci et al., 2014; Teter et al., 2005). Additionally, there were some unique
motivations that were mentioned. These included, “I ran out of my own prescription” (Gallucci
et al., 2014), “prevent the academic advantage of others” (Gallucci et al., 2014),
aphrodisiac/enhance sexual performance (Lookatch et al., 2012; Lord, Brevard, & Budman,
2011), increase energy to exercise/enhance athletic performance (Judson & Langdon, 2009;
Lookatch et al., 2012; Low & Gendaszek, 2002), “makes me feel more confident and social”
(Clegg-Kraynok et al., 2011) and “safer than street drugs” (Ghandour et al., 2012; McCabe et al.,
2007).
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Other trends in stimulant motivation results. There were three studies that listed nonacademic motivations. However, all of these studies focused only on specific motivations not
related to stimulant medications intended uses. For example, Upadhyaya and colleagues (2005)
investigated 334 college students at one university who used prescription stimulants nonmedically to get high, which occurred in 25% of students who reported having a prescription for
stimulants. The other two studies focused on the motivation to use stimulant medications nonmedically for weight loss, with prevalence rates of this motivation ranging from 4% to 12% in
two samples of approximately 700 undergraduate students at the same university (Jeffers,
Benotsch, & Koester, 2013; Jeffers & Benotsch, 2014). No sex differences were reported. In the
one sample, the authors found that weight loss motivation was related to a variety of other
problems including more body image concerns, more use of illicit drugs, more eating disorder
symptoms, including using vomiting and other pills (e.g., laxatives, diet pills) for weight control
(Jeffers & Benotsch, 2014). All of these studies are limited by the fact that they only assessed
one potential motivation for NMUPD and only investigated students at one university per
sample. Additionally, all were cross-sectional.
Evidence that motivations change over time in young adulthood. The most
comprehensive study of motivations across this developmental period was conducted by GarnierDykstra and colleagues (2012). In the only longitudinal study, the authors investigated the nonmedical use of prescription stimulants across four years in a sample of 1,253 undergraduate
students in a large, public university in the mid-Atlantic region (ages 17-19 years) with in-person
interviews. Motivations were assessed by recording the participants’ verbatim responses to the
question, “What were the reasons you had for using <prescription stimulant>?” Answers were
then coded into one of five categories. The results found that across all time points, using
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prescription stimulants to “improve focus/study/work” remained the most reported motive for
non-medical use and increased over time. Additionally, curiosity/experimentation motivations
significantly decreased over time. There were no significant changes in the following motives: to
get high, to stay awake to party, and other. However, it should be noted that this study only
included students at one university.
Studies including young adults not in higher education. The only study that did not
exclusively investigate a student population in the United States found that motivations to use
stimulants non-medically in young adults are similar to those in college. In a sample of 3,307
young adults (ages 18 to 25) recruited from the Harris Poll Online panel, the most frequently
reported motive was, “to be more productive” (Upadhyaya et al., 2010). Across different
formulas of stimulant medications, young adults also reported using stimulants non-medically for
recreational reasons (22%-43%). These results highlight that recreational motives for use are
important in the young adult population in general as well, and not just for young adults in
collegiate settings. Additionally, there may not be many differences for why individuals are
motivated to engage in NMUPD based on whether they attend college or not. Unfortunately
differences in motivations based on whether individuals were enrolled in college or not was not
tested in this study. Therefore, definitive conclusions about the lack or presence of differences in
motivations between these populations cannot be made.
Stimulant motivation results in non-American samples. In studies conducted outside the
United States, Barrett and colleagues (2005) surveyed the motives of 50 Canadian students who
solely reported the non-medical use of stimulant medication methylphenidate. The results
indicated that out of the two options provided, most students (70%) categorized their nonmedical use as recreational, while the rest reported using methylphenidate as a study aid. The co-
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occurrence of these motives was not assessed. Franke and colleagues (2011) sampled 1,547
pupils (i.e., students in grammar school, public vocational schools, or young adults preparing for
university or obtaining a job) and university students in Germany. However, the only motivation
assessed was using stimulant medications for solely cognitive enhancement purposes. Overall,
rates were low in the sample (0.1-1.3% over time), with males reporting more non-medical use
of prescription stimulants for cognitive enhancement as compared to females for pupils. No sex
differences were found in the university student sample. Ghandour and colleagues (2012)
assessed the non-medical motives of 570 Lebanese students, and found that most university
students sampled reported using stimulant medications for their prescribed purposes and for
academic reasons (e.g., to concentrate, increase alertness, help study). Unlike most of the other
studies, but similar to the results of Canadian students (Barrett et al., 2005), a sample of 1,517
undergraduate and postgraduate students in the United Kingdom reported using stimulants nonmedically mostly for pleasure, to lose weight, or “to play sport,” with academic motives for use
being the least endorsed (Holloway & Bennett, 2012).
Summary. Based on the large amount of research conducted to date in different
universities it can be concluded that most young adults in collegiate settings are motivated to use
prescription stimulants non-medically to experience the intended effects of stimulant
medications. Additionally, it appears that recreational motives also are common, though
prevalence rates are more varied across samples. Further, conclusions about the motivations to
engage in the non-medical use of prescription stimulants for young adults not attending college is
questionable given that only two studies have included participants from this population, and the
two studies were from different countries, making conclusions based on similarities or
differences difficult as culture may account for some of the differences. There do appear to be
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differences in motivations based on country, with some young adults outside of the United States
reporting more recreational motives. Given the limited studies conducted outside of the United
States this conclusion should be made with caution.
Motivations for the non-medical use of opioids. Seven studies have investigated the
motivations for the non-medical use of prescription opioids in entirely young adult samples. Of
these articles, five were conducted in the United States, two out of the United States, and all were
in college student samples. Relieving pain was a popularly reported motivation, although it was
not consistently the most frequently reported motivation. Relieving pain was typically followed
by reports of more recreational motives like to have fun, get high, and curiosity.
Opioid motivation results in United States samples. Lord and colleagues (2011) focused
solely on the motivations for the misuse of opioid prescriptions in a sample of 527 American
collegiate students in four-year institutions using the social media site Facebook to recruit
participants. The authors found that the most common motivations were not necessarily related
to the intended uses of the medication, as most students reported using prescription opioids to
relax, followed by have fun. Only 19% of students reported using prescription opioids to manage
chronic pain, and improving sleep was not listed as a motive in the initial checklist, but was
provided by at least one participant in the additional write in category. When sex differences of
motivations were investigated, males were more likely to report using opioid prescriptions for
the non-medical uses of getting high and having fun as compared to females. Females on the
other hand were more likely to report being motivated to misuse opioids to cope with depression
or anxiety, to help with chronic pain, and to manage weight. Finally, students who had begun
misusing prescription opioids before college reported the motives “to get high” and “to have fun”
more frequently than those students who began misusing in college. A methodological strength
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of this study was that included students from a variety of colleges. However, as compared to
other research the smaller sample size suggests that selection bias may be more prominent in this
sample compared to others, especially because no incentive was offered for participation in the
study.
Some of the same authors investigated motives using similar questions in a subset of
young adults; 950 PharmD students in a college of pharmacy in the United States training to
become pharmacists (Lord et al., 2009). The results suggested that similar to the findings of
American college students in general, students primarily used prescription opioids non-medically
to have fun and relax. Although in this sample, more students did report using prescription
opioids to manage chronic pain (23%). Further, the motivation to improve sleep was specifically
queried in this study with 20% of the sample reporting using opioids for this purpose. In regards
to sex differences, men were more likely to use opioids non-medically to get high.
McCabe and colleagues (2009) investigated motivations for opioid use as well and found
within their lifetime most undergraduates from their sample of 3,639 students attending a large
public research university used prescription opioids for self-treatment motives only. This was
followed by a combination of self-treatment and recreation motives (mixed subtype) and then
recreational only motives. However, there was a slightly different pattern for past year
prescription opioid non-medical use. For participants reporting past year non-medical use, more
students reporting mixed motivations (self-treatment and recreational), followed by selftreatment only motives, with the least number of students endorsing recreational only motives
again. There were sex differences in motivational subtypes. More females reported self-treatment
motives for prescription opioids, while males endorsed more recreational and mixed motivation
subtypes. Further, students from the recreational subtype were more likely to endorse binge
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drinking, alcohol abuse, other illicit drug use, and drug abuse. However, more students from the
recreational subtype also reported using treatment services for substance use the most of all
subtypes, although the frequency was still low (10.3%). It is important to note that students in the
self-treatment subtype did not significantly differ than students who endorsed no non-medical
use of prescription opioids on these measures.
Within the same sample, research that focused more specifically on the motivations for
the non-medical use of prescription opioids was conducted analyzing the responses from 4,580
undergraduate students completing the online survey (McCabe et al., 2007). The main
motivation reported was to use the drug non-medically as clinically intended, to relieve pain. The
next two most common motives were: to get high and because of experimentation. To help with
sleep was the fourth most common motive reported. Type of motivation was found to be
important in relation to other substance use and substance-related problems, such that students
who reported motivations other than to relieve pain were more likely to report binge drinking,
alcohol problems, using illicit drugs, and experiencing more drug use related problems,
compared to non-medical users using for pain relief and non-users. Students who reported
misusing prescription opioids for pain were more likely than non-users to endorse using
marijuana or other illicit drugs only; no other substance abuse behaviors were significantly
different. The authors again found sex differences for some motivations. Males were more likely
than females to report using prescription opioids to get high, for experimentation, because they
believed they were safer than street drugs, and to counteract the effects of other drugs. There
were no sex differences for the motivations of pain relief, to help sleep, and to decrease anxiety.
Using a smaller sample, Rozenbroek and Rothstein (2011) assessed the motivations for
the non-medical use of prescription opioids of 413 undergraduate college students using an in
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class survey. The authors found that most students reported using the medications to “feel good,”
followed by curiosity, and other motivations. No participants reported using them to improve
their sleep. Unfortunately, the motive to help manage pain was not directly assessed, a prominent
weakness in this study.
Opioid motivation results in non-American samples. The research study conducted in
Lebanon also investigated the motivations for prescription opioid non-medical use (Ghandour et
al., 2012), which was the most commonly reported prescription drug used non-medically in the
sample. The main motives reported included using the drug as it was clinically intended (i.e.,
relieves pain, helps sleep), followed by decreasing anxiety and experimentation. The study
conducted in the United Kingdom found similar results, with an overwhelming majority of
students being motivated to use prescription opioids non-medically to relieve pain (Holloway &
Bennett, 2012), although sleep was not assessed. Opioids also were the most commonly reported
prescription drug used non-medically in this sample as well.
Summary. Strong conclusions about the motivations for the non-medical use of
prescription opioids is difficult to determine at this time given the limited amount of research
conducted thus far. Further, two of the studies with the largest sample sizes came from the same
sample of undergraduate students limiting the generalizability of their findings. The results
therefore are equivocal for whether young adults are motivated to use prescription opioids nonmedical to treat pain or for more recreational purposes in the United States, especially
considering that not all of the studies assessed pain relief as a possible motivation for use.
However, there is an emerging trend that more college students in the United States use
prescription opioids recreationally as compared to students in other countries. Further, as no
studies included young adults not attending college the motivations for the non-medical use of
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prescription opioids in this population is yet to be determined. On the other hand, there were
consistent sex differences noted, primarily that men were more likely to report using prescription
opioids non-medically for recreational reasons compared to women.
Motivations for the non-medical use of CNS depressants. Five studies have
investigated the motivations for the non-medical use of prescription CNS depressants in young
adult populations along with the other prescription medications described above. Of these
articles, three were conducted in the United States, two outside of the United States, and all were
in student samples. In three studies to use the drugs as clinically intended (e.g., to sleep, to
relieve anxiety) was the most reported motivation. While in one study the general motive “makes
me feel good” was most commonly reported (Rozenbroek & Rothstein, 2011) and to get high
was the most reported in another (Stone & Merlo, 2011). Across studies to get high and curiosity
motives were the next most frequently reported motivations.
CNS depressant motivation results in United States samples. One study of 413
American college students investigated CNS depressants as a whole group of medications. Using
an in-class survey researchers found that the majority of students used CNS depressants to feel
good, followed by curiosity, and then to perform better at school (Rozenbroek & Rothstein,
2011). Stone and Merlo (2011) on the other hand focused on benzodiazepines specifically. In
their sample of 383 mainly undergraduate university students most used benzodiazepines
specifically to get high or “party,” followed by to relax or “zone out.” A large number of
students also endorsed “other” reasons which were not detailed in the study. Both of these
studies had small samples of the total college student population (approximately 12,000 to
32,000 students, respectively), suggesting that selection bias may have occurred in these studies.

28

McCabe and colleagues (2009), discussed above, divided CNS depressants into sleeping
and sedative/anxiety medications. Within the motivation subtypes, most students reported using
sleeping medications for self-treatment only, across lifetime and past-year use. Though there
were differences in prevalence rates based on sex for motivational subtypes for sleeping
medication the differences were small (i.e., largest difference for self-treatment subtype, 2.9%
female:2.1% male). For sedatives/anxiety medications and both lifetime and past-year use, the
most popular subtype was recreational only, followed by the mixed subtype, with the least
amount of students endorsing the self-treatment only subtype. The differences in motivation
subtype based on sex were more prominent, with more females categorized in the self-treatment
only subtype, and more males in the recreational only and mixed subtype.
CNS depressant motivation results in non-American samples. Two studies investigated
the non-medical use of CNS depressants in samples outside of the United States. Along with the
other prescription medications described above, Ghandour and colleagues (2012) researched the
motivations for CNS depressants in Lebanese students. These authors categorized anxiety and
sleeping medications separately. In line with their other results, the authors found that students
from their sample were motivated to use both sleeping and anxiety medications primarily for
their clinically intended purposes, though there were still many students who endorsed using
CNS depressants for other reasons like to get high or counteract the effects of other drugs. In the
sample of university students from the United Kingdom, a similar categorization of CNS
depressants was made, but the two categories were labeled sleeping aids and sedatives
(Holloway & Bennett, 2012). The main motives for non-medical use also were to use the
medications as clinically intended, but the second most commonly reported reason for both was
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to get high. However, this motive was much less frequently endorsed for sleeping aids (6%) as
compared to sedatives (27%).
Summary. Similar to the work on prescription opioids, positive assumptions about the
motivations for the non-medical use of prescription CNS depressants is difficult to determine
given the limited literature on this topic to date. However, there is an emerging trend that CNS
depressants used for sleeping may be more likely to be used as clinically intended compared to
sedative and anxiety medications. Again, as no research was conducted on non-student
populations the motives for these young adults to use is not currently known. In terms of sex
differences, there is emerging evidence that females may be more likely to use CNS depressants
non-medically for reasons they are prescribed, while males may be more likely to use them for
recreational reasons.
Motivation findings across prescription drug classes. Two studies looked at
motivations across prescription drug classes to assess NUMPD in general, not limited by
prescription drug class. Both of these studies were discussed above and were cross-sectional
research using college students as participants. One study was conducted in the United States and
focused on sex differences in the motivations for NMUPD in general (McCabe et al., 2009). The
other study was conducted in Lebanon and investigated if motivations across prescription drug
class for NMUPD differed based on where young adults got their prescriptions (Ghandour et al.,
2012).
McCabe and colleagues (2009) found sex differences across prescription drug classes in
their sample of American college students. For instance, women reported more self-treatment
motives as compared to men, while men reported more recreational and mixed (self-treatment
and recreational) motives. Ghandour and colleagues (2012) found that type of motivation varied
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not only based on prescription medication class, but also based on other variables. For example,
Lebanese students who reported obtaining sleeping, anxiety, and pain medications from their
parents in general were using them for their intended purpose. Similarly, students who obtained
their stimulant medications from a doctor or pharmacist reported using the medication nonmedically for its intended purpose only, though it was not how the doctor prescribed the
medication. However, students who obtained stimulants from friends and family members other
than parents were more likely to report using the medication for other unintended purposes (e.g.,
to get high).
As these were the only two studies to research the motivations for NMUPD across
multiple prescription classes and they occurred in different cultures and investigated different
variables it is difficult to draw overall conclusions from their findings. Still, though varied, these
results suggest that motivations for NMUPD are influenced by different factors. Also, the
findings are a reminder that context matters when researching motivations and needs to be
considered when interpreting results from any study.
Difficulties in reviewing NMUPD motivation results. There are many reasons why
evaluating research on NMUPD as a whole is difficult. First, the definition of “non-medical” use
varies between studies. Some definitions only include illegal act of using a medication without a
prescription, or researchers remove participants from their data set who report having a
prescription for medications (e.g., DeSantis et al., 2008; Dussault & Weyandt, 2013; Franke et
al., 2011; Jeffers & Benotsch, 2014). Eliminating these participants is concerning because they
may still be using their own prescription non-medically. Indeed, studies that have included and
analyzed data of young adults who do have prescriptions for medications find that participants
are using their medications non-medically. For example, in terms of stimulant medications
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prevalence rates of young adults using their own prescription non-medically range from 2% to
47% in studies discussed. Further, differences in motivations were noted in at least two of these
studies. Results found that individuals who misuse others’ prescriptions reported more
recreational motives than those who use their own medications non-medically (Gallucci et al.,
2014), or used prescriptions less “to control ADHD symptoms” (Hartung et al., 2013). These
findings suggest that both groups of young adults need to be considered when investigating
NMUPD and studies that have not included students who have a prescription for medications
may be underreporting the prevalence of NMUPD. Further, only studies with prescription
stimulants have specifically looked at the differences between these populations. It is not clear if
similar findings exist for prescription opioid and CNS depressant non-medical users.
Other studies have included participants who have a prescription but ask about tolerance
(e.g., use for longer periods than prescribe; Ghandour et al., 2012) and motives in their “nonmedical” definition (e.g., for reasons other than indicated by a prescription; Lord et al., 2009).
Additionally, one researcher only included the motive “to get high” to infer NMUPD
(Upadhyaya et al., 2005). Other researchers do not state that they defined NMUPD, thereby
leaving the definition of “non-medical” use to the discretion of the participants (e.g., Rozenbroek
& Rothstein, 2011; Stone & Merlo, 2011; Tuttle et al., 2010; Weyandt et al., 2009). This lack of
consistency across studies makes comparisons difficult and drawing conclusions complicated.
Another inconsistency in the research is that different medications were grouped and
termed differently across studies (e.g., sedative/anxiety vs. sleeping pills, etc.). In particular,
CNS depressants had the most varied definition across studies. This is probably because CNS
depressants cover a variety of medications. Only one study grouped CNS depressants together
into a single category (Rozenbroek & Rothstein, 2011). However, using the broad category of
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CNS depressants may not allow researchers to find differences in motivations between the
categories within that class of medication. For instance, McCabe and colleagues (2009) found
differences between different motivational subtypes. The self-treatment subtype was the most
prevalent for the non-medical use of sleeping medications, where the recreational subtype was
most prevalent for sedative/anxiety medications. University students in the United Kingdom also
endorsed using sedatives more to get high as compared to sleeping aids, as they were defined in
the study (Holloway & Bennett, 2012). Therefore, results that group different types of CNS
depressants together may be missing some of the subtleties between the different types of
medications.
Motivations also were not consistently assessed across studies. Some studies included
very broad motivations (e.g., “makes me feel good,” Rozenbroek & Rothstein, 2011). This
makes it difficult to pinpoint non-medical users real motivation as it is unclear to determine if
they were using the drug as it was intended for example, or for other more recreational reasons.
Most other studies had more specific motivations listed, and found differences in the more
nuanced responses. Other studies combined motivations like “to help me study/perform better at
school” (Rozenbroek & Rothstein, 2011). These motives are double-barreled, and there may be
students who are non-medically using prescription drugs for self-treatment reasons (e.g., using
opioids to treat chronic pain) and therefore, it may help them perform better at school which is
different than using that medication to help them study. The lack of specificity may make
findings difficult to interpret and may not be as helpful in developing prevention or intervention
efforts.
Two studies used a specific scale to assess the motivations to use prescription drugs nonmedically. Dussault and Weyandt (2013) used the Stimulant Survey Questionnaire (SSQ),
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developed by Weyandt and colleagues (2009) for the study of the non-medical use of
prescription stimulant medications. Within this scale, participants were able to rate their
likeliness of different motivations for the non-medical use of stimulants on a scale of 1 (never) to
5 (always). The reliability for this factor was the strongest of all the scales factors though (α =
.92). However, within the scoring of this scale motivations are not specifically highlighted, but
are grouped together in a factor with other questions about context (e.g., use at parties),
administration (e.g., “I have snorted prescription stimulants”), beliefs about harm (e.g., “using
prescription stimulants occasionally is harmless”), knowledge about prescription stimulants and
being offered prescription stimulants. This can make interpretations from studies using these
scaled more difficult as more than just motivations are considered, confounding potential
outcomes. Further, this scale only assesses motivations for the use of prescription stimulants.
Other authors reported piloting their questions first (DeSantis et al., 2008; McNiel et al.,
2011), while others stated that they based their questions on previous research (Clegg-Kraynok et
al., 2011; Gallucci et al., 2014; Hall et al., 2005; Hartung et al., 2013; Jeffers & Benotsch, 2014;
Judson & Langdon, 2009; Stone & Merlo, 2011). One study reported using both methods
(Holloway & Bennett, 2012). However, almost all modified the motivations provided in previous
work. Garnier-Dykstra and colleagues (2012) and Lookatch and colleagues (2012) on the other
hand, recorded students answers and then coded them into motivational categories. Finally, some
of the studies had young adults choose or list one motive (Barrett et al., 2005; Dupont et al.,
2008; Franke et al., 2011; Gallucci et al., 2014; Holloway & Bennett, 2012; McNiel et al., 2011;
Rozenbroek & Rothstein, 2011; Stone & Merlo, 2011; Upadhyaya et al., 2010), while the rest
allowed for the selection of multiple motivations (Advokat et al., 2008; Bavarian et al., 2013;
Clegg-Kraynok et al., 2011; DeSantis et al., 2008; Dussault & Weyandt, 2013; Garnier-Dykstra
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et al., 2012; Ghandour et al., 2012; Hall et al., 2005; Hartung et al., 2013; Herman et al., 2011;
Judson & Langdon, 2009; Lookatch et al., 2012; Lord et al., 2009; McCabe et al., 2009; Peterkin
et al., 2011; Prudhomme White et al., 2006; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, &
Swartzwelder, 2009a; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & Swartzwelder,
2009b; Teter et al., 2005; Teter et al., 2006; Tuttle et al., 2010; Weyandt et al., 2009). The
varying measurement models add to the complication of interpreting results across studies.
Limitations of past research. The overwhelming majority of the work on motivations
for NMUPD in young adults is limited in scope. Most of the research has been conducted crosssectionally on motivations for the non-medical use of stimulant medications in student samples
from the United States. There is especially a lack of longitudinal research in this population, as
well as studies on the motivations to use CNS depressants non-medically. Also, although a few
more studies have investigated the motives for opioid non-medical use, there is still a dearth of
knowledge in this area. Since, as expected due to their different therapeutic properties, the
motivations behind the different classes of prescription medications vary, this research is
imperative and may be able to further prevention and intervention efforts that focus not only on
stimulants, but on prescription opioids and CNS depressants as well.
Research on motivations also needs to include young adults who are not currently
students in higher education. Only two studies reached out to young adults in other areas. Franke
and colleagues (2011) included young adults in Germany who were in vocational training,
preparing for university or obtaining a job. Upadhyaya and colleagues (2010) used the Harris
Poll Online panel to connect to young adults outside of academia in the United States.
Impressively, through different sampling techniques, about half of the sample in Upadhyaya and
colleagues (2010) consisted of young adults that did not identify as college students. Given that
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this sample reported using stimulants non-medically both as the medications were intended and
for recreational purposes, similar to college students, there may be some similar treatment
approaches to both groups. As both of these studies only investigated the motives for nonmedical stimulant use, there is a need for research on the motivations for non-college enrolled
young adults’ non-medical use of other prescription medications. However, it is important to
note non-medical use of at least stimulants tends to be more prevalent in full-time college
students as compared to those who are not in college or are only part-time students (SAMHSA,
2009). This suggests that young adults not in college may be at less risk for these behaviors and
the associated negative outcomes. More research needs to be conducted with other prescription
medication classes to determine if this pattern is replicated.
Present Study
NMUPD is a significant and growing public health concern with young adults at great
risk for use, abuse, and related negative outcomes. The most substantial gap in the current
literature is the lack of comprehensive longitudinal investigations assessing motivations for
NMUPD for multiple prescription drug classes in a representative sample of young adults and
how these motivations may change over time. The present study contributes to the literature on
NMUPD by addressing some of the limitations in previous research investigating the motivations
to use prescription drugs non-medically. First, the sample consisted of a nationally representative
sample of young adults that have been followed longitudinally across three biennial follow-up
waves (modal ages 19/20 to 23/24 years from wave 1 to 3). With this sample, information about
how motivations change over time in a representative sample of young adults were assessed.
Also, if there are differences over time for motivations for NMUPD of young adults based on
sex, or who attend college, was researched. If motivations are different for young adults who
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endorsed using in high school, or if motivations for NMUPD change over time for new users
were investigated as well. Further, specific motivations for the non-medical use of prescription
stimulants, opioids, and CNS depressants were studied, expanding the knowledge on less
researched prescription drug classes. The strengths of the present study clearly advance the
current NMUPD literature.
This study has the potential to help prevention and intervention efforts in several ways.
For example, by identifying if motivations change over time, developmentally appropriate efforts
to reflect these changes can be enacted. Additionally, if the change in motivations is different for
young adults in college as compared to their peers not in college, or based on sex, the best ways
to intervene with these unique populations can be better understood to increase effectiveness.
Finally, results from this study can help to explain if there are differences in motivations for
young adults who started NMUPD in high school or if there are changes in motivations over time
for new users. These findings in particular can help to inform prevention efforts by targeting
what motivates young adults to initiate NMUPD.
A series of generalized estimating equations (GEE) repeated measure analyses tested
variations in motivations of NMUPD through secondary data analyses. Separate equations were
developed for each of the following: (1) non-medical use of stimulants, (2) non-medical use of
CNS depressants, and (3) non-medical use of prescription opioids. Following the bivariate
analyses, each equation was reestimated to test if sex or attending college moderated the relation
of motivations for NMUPD over time. Binary logistic regression models were then used to
estimate if individuals who reported NMUPD in high school endorsed different motivations than
individuals who reported initiating use in wave 1 (e.g., beginning of young adulthood). Finally,
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GEE models tested whether NMUPD motivations changed over time for new users. Again,
separate analyses were conducted for each class of prescription drugs.
Based on the developmental theory of young adults and previously examined research the
following results are hypothesized.
Statement of the Hypotheses
Hypothesis 1. It is predicted that the motivations to feel good or get high, for
experimentation, and boredom will decrease over time across all prescription drugs classes as
young adults move towards more stability.
Hypothesis 2. It is predicted that “self-treatment” motives (i.e., stimulants: to stay awake,
to get more energy, to help me study, and to help me lose weight; opioids: to relax or relieve
tension, to get sleep, and to relieve physical pain and; CNS depressants: to relax or relieve
tension, and to get sleep) as well as addiction motives (i.e., because I am “hooked”—I feel I have
to have them) will increase over time across all prescription drug classes as exposure to
prescription drugs and the risk for psychiatric problems increases.
Hypothesis 3. It is predicted that there will be no change over time in the following
motives: to seek deeper insights and understanding, because of anger or frustration, to get
through the day, to increase the effects of some other drug(s), to decrease (offset) the effects of
some other drug(s), as a substitute for heroin, and to control coughing.
Hypothesis 4. It is predicted that sex differences will be observed for CNS depressant
and opioid prescription drug classes, such that males will endorse more recreational motivations
(i.e., to experiment, to feel good or get high, to seek deeper insights and understanding, to have a
good time with my friends, to fit in with a group I like, because of boredom, to increase or
decrease the effects of some other drug(s)e (offset) the effects of some other drug(s)), as
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compared to females who will report more self-treatment motivations, or using the medications
as they are clinically intended. Moderation analyses are largely exploratory given the lack of
previous research in this area.
Hypothesis 5. It is predicted that college attendance will not moderate the relations of
change of motives over time across all prescription drug classes, such that both young adults in
and out of college will experience the same changes in motives over time because they are all
experiencing the same developmental life stage and associated changes.
Hypothesis 6. It is predicted that young adults who started NMUPD in high school,
compared to their peers who initiated NMUPD right after high school will be more likely to
endorse recreational motivations.
Hypothesis 7. It is predicted that over time the motivations for new non-medical users of
prescription drugs will be similar to those of continued users, such that all young adults
experience the same changes in motivations over time because they are all experiencing the same
developmental life stage and associated changes.
Method
Participants
The sample consisted of 14,990 participants who were surveyed in their first, second, and
third biennial follow-up surveys following high school completion (waves 1, 2, and 3,
respectively) from 1976 to 2013 as part of the Monitoring the Future (MTF) project. Due to the
aims of the proposed study and concerns about sample size, the 36 cohorts were combined and
the analyses were conducted on all available data. After accounting for sampling bias, the sample
consisted of 48% male and 73% White participants (weighted). Based on previous studies
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analyzing similar data from this project, the retention rate was estimated to be just below 50%
(McCabe et al., 2014).
Measures
Using six randomly distributed questionnaire forms, the MTF assesses demographic and
psychosocial characteristics and standard measures of substance use.
Demographics. Demographics were assessed at wave 1 and consisted of participant selfreports of age, sex (i.e., male/female), race/ethnicity (i.e., White/non-White), and if they were
enrolled in an academic course (i.e., During March of this year, were you taking courses at any
school or college?).
NMUPD. NMUPD was assessed at all three waves with items asking respondents on
how many occasions (if any) they had used prescription medications on their own, without a
doctor’s orders during the past 12 months. There were separate questions for each prescription
medication class: (1) prescription stimulants (e.g., Dexedrine, Ritalin, Adderall, Concerta,
Methamphetamine); (2) prescription CNS depressants/tranquilizers (e.g., Librium, Valium,
Xanax, Soma, Serax, Ativan, Klonopin); and (3) prescription opioids (e.g., Methadone, Codeine,
OxyContin, Percodan, Opium, Demerol, Percocet, Ultram, Morphine, and Vicodin). The
response scale was (1) no occasions, (2) one to two occasions, (3) three to five occasions, (4) six
to nine occasions, (5) 10–19 occasions, (6) 20–39 occasions and (7) 40 or more occasions.
Motivations for NMUPD. Motivations for NMUPD were assessed by asking
participants who reported past-year NMUPD to indicate the most important reasons for NMUPD
from a check-all-that-apply list of binary items. As noted in Table 1, all prescription drug classes
listed the following motives: (a) to experiment—to see what it’s like, (b) to relax or relieve
tension, (c) to feel good or get high, (d) to seek deeper insights and understanding, (e) to have a
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good time with my friends, (f) to fit in with a group I like, (g) to get away from my problems or
troubles, (h) because of boredom, nothing else to do, (i) because of anger or frustration, (j) to get
through the day, (k) to increase the effects of some other drug(s), (l) to decrease (offset) the
effects of some other drug(s), and (m) because I am “hooked”—I feel I have to have them.
Table 1.
NMUPD motivations assessed by prescription drug class
Stimulants
1. To experiment—to see
what it’s like
2. To relax or relieve tension
3. To feel good or get high
4. To seek deeper insights and
understanding
5. To have a good time with
my friends
6. To fit in with a group I like
7. To get away from my
problems or troubles
8. Because of boredom,
nothing else to
do

CNS depressants
1. To experiment—to see
what it’s like
2. To relax or relieve tension
3. To feel good or get high
4. To seek deeper insights and
understanding
5. To have a good time with
my friends
6. To fit in with a group I like
7. To get away from my
problems or troubles
8. Because of boredom,
nothing else to do

Opioids
1. To experiment—to see
what it’s like
2. To relax or relieve tension
3. To feel good or get high
4. To seek deeper insights and
understanding
5. To have a good time with
my friends
6. To fit in with a group I like
7. To get away from my
problems or troubles
8. Because of boredom,
nothing else to do

9. Because of anger or
frustration
10. To get through the day
11. To increase the effects of
some other drug(s)
12. To decrease (offset) the
effects of some other
drug(s)
13. To stay awake
14. To get more energy
15. To help me lose weight
16. Because I am “hooked”—I
feel I have to have them
17. To help me study

9. Because of anger or
frustration
10. To get through the day
11. To increase the effects of
some other drug(s)
12. To decrease (offset) the
effects of some other
drug(s)
13. To get sleep
14. Because I am “hooked”—I
feel I have to have them
15. To relieve physical pain

9. Because of anger or
frustration
10. To get through the day
11. To increase the effects of
some other drug(s)
12. To decrease (offset) the
effects of some other
drug(s)
13. To get sleep
14. As a substitute for heroin
15. Because I am “hooked”—I
feel I have to have them
16. To relieve physical pain
17. To control coughing
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Specific motives for stimulants included: (a) to stay awake, (b) to get more energy, (c) to
help me study, and (d) to help me lose weight. Both CNS depressants and opioids included the
motives, “to get sleep,” and “to relieve physical pain.” Opioids had the additional motives, “as a
substitute for heroin,” and “to control coughing.”
Procedures
According to the MTF website (The Regents of the University of Michigan, 2014), the
MTF project begun in 1975 with the goal to study changes in the beliefs, attitudes, and behavior
of young people in the United States. The MTF project is a repeated series of surveys in which
the same segments of the population (8th, 10th, and 12th graders; college students; and young
adults) are presented with the same set of questions over a period of years to see how answers
change over time. The project has been conducted under a series of research grants from NIDA,
a part of the National Institutes of Health. Surveys have been carried out each year since 1975 by
the University of Michigan Survey Research Center. The MTF uses a three-stage sampling
procedure to gather a nationally representative sample of students. In stage 1, geographic areas or
primary sampling units are selected; in stage 2, schools within primary sampling units are
selected (with probability proportionate to class size); and in stage 3, students within schools are
selected. Within each school, up to 350 students may be included. In schools with fewer
students, the usual procedure is to include all of them in the data collection. In larger schools, a
subset of students is selected either by randomly sampling entire classrooms or by some other
random method that is judged to be unbiased.
For the in-school survey, about 10 days before the administration, the students are given
flyers explaining the study. Also, advance letters to parents inform them about the study and
provide them a means for declining their child's participation if they so desire. The actual
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questionnaire administrations are conducted by the local Institute for Social Research
representatives and their assistants, following standardized procedures detailed in a project
instruction manual. The questionnaires are group administered in classrooms during a normal
class period whenever possible; however, circumstances in some schools require the use of larger
group administrations. For those students selected to participate in the follow-up surveys, the
questionnaires are mailed to the participants with a return, self-addressed, stamped envelope and
a small monetary gift from the University of Michigan as a token of appreciation. Because so
many questions are included in the MTF, much of the questionnaire content is divided into six
different questionnaire forms, which are randomly distributed. This approach results in six
virtually identical subsamples. The questionnaires sent in the follow-up survey are directly
comparable to the base year questionnaires, both in content and in numbers of questionnaire
forms. The measures relevant for this study were asked on Form 1; therefore, this study focused
on the subsamples receiving Form 1 within each cohort.
Each year about 16,000 students in approximately 133 public and private high schools
nationwide participate by completing surveys administered in classrooms. A randomly selected
sample of approximately 2,400 students from each senior class is followed up biannually after
high school on a continuing basis. These respondents receive the mail questionnaire at their
home, which they complete and return to MTF. The biennial follow-up surveys begin 1 year
after high school for one random half of each cohort and 2 years after high school for the other
half (for more information on the procedures see Bachman, Johnston, & O'Malley, 2014). For
the purpose of the current study, the two halves were combined (combining modal ages 19/20,
21/22 and 23/24 years) due to sample size concerns and reported lack of significant differences
across the two halves on substance use measures (McCabe et al., 2014). The student response
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rates for high school seniors ranged from 77% to 85% between 1976 and 2012 (Bachman et al.,
2014). The follow-up panel data for surveys through wave 3 is estimated to be approximately
just below 50% (Bachman et al., 2014; McCabe et al., 2014).
Data Analysis
First, sampling weights were used to correct for any unequal probabilities of selection
that occurred at any stage of sampling for all analyses so the results could be generalized to the
national population. Then, descriptive statistics were calculated to examine the frequencies and
distribution properties of each variable, as well to gain a better understanding of the sample
demographics. This was followed by a test to determine if the missing data was missing
completely at random (MCAR).
A series of generalized estimating equations (GEE) repeated measure analyses tested
variations in motivations of NMUPD using SPSS Version 23. GEE models were used because of
their flexible approach to handling correlated data structures that arise from repeated measures of
the same individuals over time (Diggle, Heagerty, Liang, & Zeger, 2013; Liang & Zeger, 1993;
Zeger, Liang, & Albert, 1988; Zeger & Liang, 1992). Further, GEE can handle binary outcome
data and time-varying and time-invariant predictors (Homish, Edwards, Eiden, & Leonard,
2010). Additionally, GEE provides population averaged estimates, which is appropriate for
nationally representative data. Although the correlation structure in GEE does not affect
the marginal parameter estimates, it does affect the standard error estimates. Therefore, the GEE
were conducted using an unstructured correlation matrix, which is a completely general
correlation matrix. This decision was based on theory, comparison to the actual correlation
matrixes, and Quasi-likelihood under Independence Model Criterion (QIC) comparisons. It
should be noted that across models there were very small differences observed in the QIC values.
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To answer the question if motivations of NMUPD change over the developmental period
of young adulthood, GEE repeated measures equations were developed for non-medical users, in
which each motive was, in turn, entered into a separate equation as the dependent variable, with
wave (i.e., time) as the repeated factor in each equation. Separate equations were developed for
each of the following: (1) non-medical use of stimulants, (2) non-medical use of CNS
depressants, and (3) non-medical use of opioids. Next, analyses were conducted to determine if
differences existed in the motivations for NMUPD based on young adults’ sex and college
attendance. Following the bivariate analyses, each equation was re-estimated with wave as the
repeated factor and the main effect of sex or college attendance and the first-order interaction of
Sex/College Attendance*Wave included in the model. For all GEE analyses, a Wald chi-square
test determined whether or not wave, sex, college attendance, and the Sex/College
Attendance*Wave interaction were significantly associated with each dependent variable (i.e.,
each motivation). For models with significant chi-square tests, pairwise comparisons of
estimated marginal means produced from these models were evaluated in order to determine
among which waves the participants differed with respect to the dependent variable. The
pairwise comparisons used a Bonferronni correction to control for the likelihood of making a
Type I error as a result of multiple comparisons.
Binary logistic regression models were then used to estimate if individuals who reported
NMUPD in high school endorsed different motives than individuals who did not report NMUPD
in high school on Wave 1 NMUPD. Each prescription drug class was investigated separately. For
example, individuals who reported non-medical use of prescription stimulants in high school
were compared to new non-medical users of prescription stimulants at Wave 1. Similarly,
participants who reported non-medical use of prescription CNS depressants in high school were
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compared to new non-medical users of CNS depressants at Wave 1. The same method was used
for prescription opioids. Therefore, the groups may not be mutually exclusive as a participant
may have endorsed non-medical use of more than one class of prescription medications either in
high school or Wave 1.
Finally, GEE repeated measures equations tested whether NMUPD motivations changed
over time for new users. Again, separate analyses were conducted for each class of prescription
drugs. Similarly as described above, GEE were developed for new non-medical users, in which
each motive was, in turn, entered into a separate equation as the dependent variable, with wave
as the repeating factor in each equation. Moderators were not included in these analyses because
of sample size concerns. Additional post hoc analyses, including exploratory latent class
analyses, are discussed in the results section.
Results
Descriptive Statistics
Table 2 reports the sample demographics including sex, race/ethnicity, age, enrollment in
college classes, and past year NMUPD for the total sample and for users, as appropriate. Of note,
most individuals reported infrequent use (1-2 times in the past year) and the percentages of users
attending college classes decreased over time for all prescription drug classes. Table 3 reports the
frequencies and percentage of users that endorsed each motivation across all waves. It should be
noted that some motives have smaller sample sizes as they were added to the study in later years.
For stimulants, the top NMUPD motivations consistently included (in terms of high frequencies):
to help me study, to stay awake, to get more energy, to feel good or get high, to experiment, and
to help me lose weight. For CNS depressants, the top NMUPD motivations consistently
included: to relax or relive tension, to get sleep, to feel good or get high, to experiment, and to
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relieve physical pain. The frequencies of NMUPD motivations for prescription opioids were
slightly more varied, but consistently included: to feel good to get high, to experiment, to relax
or relieve tension, and to relieve physical pain. Table 4 reports the frequencies, means, and
standard deviations of the number of motivations endorsed by users by prescription drug class to
gain a better understanding of how many motives were endorsed overall. Across all prescription
drug classes it was common to endorse more than one motive, but not more than four or five
motives across all waves.
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Table 2.
Sample demographics for total sample and past year NMUPD users by prescription drug class
Demographic
N
Sex (n, % male)

Total sample
12,223
5,789 (47.5)

Race/ethnicity
(n, % White)

8,736 (72.5)

Stimulants
Wave 1 Wave 2
288
273
(43.6)
(44.7)
582
529
(88.6)
(87.6)

Wave 3
185
(47.5)
335
(85.8)

CNS depressants
Wave 1 Wave 2
123
126
(36.1)
(40.9)
295
273
(88.3)
(89.1)

Wave 3
119
(40.8)
254
(86.6)

Opioids
Wave 1
153
(41.9)
322
(88.6)

Wave 2
148
(43.1)
301
(89.6)

Wave 3
113
(42.1)
231
(86.1)

N of users
Age (M(SD))a

Wave 1
9,237
19.52
(0.46)

Wave 2
8,629
21.49
(0.44)

Wave 3
7,836
23.47
(0.43)

757
19.43
(0.26)

724
21.47
(0.26)

466
23.38
(0.26)

428
19.51
(0.24)

444
21.42
(0.23)

406
23.52
(0.24)

549
19.49
(0.24)

492
21.49
(0.29)

376
23.47
(0.28)

Taking college
classes (n, %)

5,753
(68.1)

4,447
(56.8)

2,193
(30.7)

398
(60.7)

295
(48.6)

113
(29.0)

203
(60.1)

148
(48.4)

84
(28.8)

251
(68.1)

192
(56.5)

88
(32.9)

7,719
(92.1)
217
(2.6)
131
(1.6)
98 (1.2)
95 (1.1)
52 (0.6)
73 (0.9)

7,152
(92.1)
214
(2.8)
133
(1.7)
77 (1.0)
78 (1.0)
51 (0.7)
61 (0.8)

6,721
(94.5)
133
(1.9)
78 (1.1)

8,023
(95.9)
183
(2.2)
78 (0.9)

7,450
(96.0)
160
(2.1)
57 (0.7)

6,820
(95.9)
147
(2.1)
57 (0.8)

7,949
(95.6)
189
(2.3)
79 (0.9)

7,396
(95.6)
174
(2.2)
77 (1.0)

6,822
(96.2)
132
(1.9)
63 (0.9)

50 (0.7)
51 (0.7)
38 (0.5)
44 (0.6)

36 (0.4)
27 (0.3)
9 (0.1)
10 (0.1)

46 (0.6)
28 (0.4)
9 (0.1)
11 (0.1)

39 (0.6)
24 (0.3)
9 (0.1)
18 (0.2)

46 (0.6)
27 (0.3)
14 (0.2)
14 (0.2)

35 (0.4)
24 (0.3)
14 (0.2)
19 (0.2)

29 (0.4)
18 (0.2)
14 (0.2)
14 (0.2)

a

Number of occasions used in
past year (n (%))
0
1-2
3-5
6-9
10-19
20-39
40+

Note. All descriptive statistics are weighted. All percentages are reported as valid percentages, not including participants who had missing
values.
a
Information provided by researchers at University of Michigan with access to full data set.
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Table 3.
Frequencies of endorsed NMUPD motivations over time and percentage of users
NMUPD Motivation

Wave 1
n (% of users)
Stimulants (n)
645
To experiment—to see what it’s like
272 (42.2)
To relax or relieve tension
73 (11.3)
To feel good or get high
254 (39.3)
To seek deeper insights and understanding
29 (4.4)
To have a good time with my friends
175 (27.1)
To fit in with a group I like
11 (1.7)
To get away from my problems or troubles
45 (7.0)
Because of boredom, nothing else to do
66 (10.2)
Because of anger or frustration
42 (6.6)
To get through the day
159 (24.7)
To increase the effects of some other drug(s)
61 (9.4)
To decrease (offset) the effects of some other drug(s) 27 (4.1)
To stay awake
416 (64.5)
To get more energy
390 (60.5)
To help me lose weight
205 (31.8)
Because I am “hooked”—I feel I have to have them
9 (1.3)
a
To help me study
35 (75.9)

Wave 2
n (% of users)
587
206 (35.1)
46 (7.9)
218 (37.2)
21 (3.5)
161 (27.4)
12 (2.0)
32 (5.5)
49 (8.4)
20 (3.3)
50 (25.6)
41 (7.0)
27 (4.7)
381 (64.8)
371 (63.1)
182 (31.0)
8 (1.3)
56 (74.9)

Wave 3
n (% of users)
376
99 (26.4)
24 (6.3)
131 (34.8)
17 (4.5)
100 (26.5)
9 (2.5)
17 (4.5)
31 (8.3)
13 (3.5)
91 (24.1)
33 (8.8)
20 (5.4)
243 (64.6)
264 (70.2)
130 (34.5)
4 (1.1)
35 (63.6)

CNS depressants (n)
To experiment—to see what it’s like
To relax or relieve tension
To feel good or get high
To seek deeper insights and understanding
To have a good time with my friends
To fit in with a group I like
To get away from my problems or troubles
Because of boredom, nothing else to do
Because of anger or frustration
To get through the day
To increase the effects of some other drug(s)
To decrease (offset) the effects of some other drug(s)
To get sleep
Because I am “hooked”—I feel I have to have them
To relieve physical painb

285
93 (32.6)
216 (75.8)
17 (40.9)
8 (2.9)
69 (24.3)
5 (1.8)
40 (14.1)
31 (11.0)
40 (13.9)
14 (4.9)
43 (15.1)
15 (5.3)
131 (45.9)
21 (7.2)
95 (32.9)

271
76 (28.2)
217 (80.1)
98 (36.2)
4 (1.5)
46 (17.1)
4 (1.5)
55 (20.4)
25 (9.2)
47 (17.5)
25 (9.1)
32 (11.8)
24 (8.9)
144 (53.3)
6 (2.3)
93 (34.3)
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313
114 (36.4)
230 (73.3)
120 (38.2)
10 (3.1)
60 (19.1)
2 (0.6)
59 (18.8)
33 (10.5)
42 (13.3)
20 (6.4)
44 (14.0)
10 (3.1)
146 (46.6)
30 (9.5)
81 (26.2)

NMUPD Motivation

Wave 1
Wave 2
Wave 3
n (% of users) n (% of users) n (% of users)
Opioids (n)
325
304
242
To experiment—to see what it’s like
168 (51.7)
120 (39.5)
79 (32.6)
To relax or relieve tension
157 (48.3)
166 (54.4)
130 (53.8)
To feel good or get high
179 (55.1)
145 (47.8)
118 (48.8)
To seek deeper insights and understanding
16 (5.0)
12 (3.8)
11 (4.7)
To have a good time with my friends
96 (29.5)
82 (26.8)
57 (23.4)
To fit in with a group I like
5 (1.4)
10 (3.2)
3 (1.1)
To get away from my problems or troubles
51 (15.8)
43 (14.1)
36 (15.0)
Because of boredom, nothing else to do
53 (16.2)
36 (11.9)
32 (13.1)
Because of anger or frustration
30 (9.2)
31 (10.2)
20 (8.1)
To get through the day
22 (6.8)
19 (6.1)
22 (8.9)
To increase the effects of some other drug(s)
55 (17.0)
47 (15.3)
34 (14.0)
To decrease (offset) the effects of some other drug(s) 9 (2.9)
8 (2.5)
11 (4.5)
To get sleep
91 (28.1)
87 (28.7)
70 (29.0)
As a substitute for heroin
6 (1.8)
7 (2.3)
6 (2.3)
Because I am “hooked”—I feel I have to have them
25 (7.8)
19 (6.4)
10 (4.3)
c
To relieve physical pain
151 (46.8)
178 (58.0)
157 (64.6)
c
To control coughing
31 (9.5)
32 (10.5)
25 (10.2)
Note. NMUPD = Non-medical use of prescription drugs. All frequencies and percentages are weighted.
a
Motivation added in 2009, sample size: Wave 1 = 46, Wave 2 = 74, Wave 3 = 55
b
Motivation added in 1981, sample size: Wave 1 = 309, Wave 2 = 288, Wave 3 = 271
c
Motivation added in 1981, sample size: Wave 1 = 324, Wave 2 = 307, Wave 3 = 242
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Table 4.
Frequencies, means, and standard deviations of number of motives endorsed by users by
prescription drug class
Number of Motives Endorsed
Stimulants (M (SD))
1 (n (% of users))
2 (n (% of users))
3 (n (% of users))
4 (n (% of users))
5 (n (% of users))
6 (n (% of users))
7 (n (% of users))
8 (n (% of users))
9 (n (% of users))
10 (n (% of users))
11 (n (% of users))
12 (n (% of users))
13 (n (% of users))
14 (n (% of users))
15 (n (% of users))
16 (n (% of users))
17 (n (% of users))

Wave 1
3.73 (2.31)
195 (16.4)
216 (18.1)
228 (19.1)
183 (15.4)
142 (11.9)
89 (7.5)
60 (5.0)
29 (2.4)
21 (1.8)
10 (0.8)
9 (0.8)
4 (0.3)
1 (0.1)
3 (0.3)
1 (0.1)
0 (0.0)
0 (0.0)

Wave 2
3.47 (2.11)
167 (17.1)
202 (20.7)
194 (19.9)
156 (16.0)
114 (11.7)
62 (6.4)
32 (3.3)
18 (1.8)
9 (0.9)
9 (0.9)
7 (0.7)
3 (0.3)
1 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

Wave 3
3.49 (2.21)
91 (14.9)
151 (24.7)
124 (20.3)
91 (14.9)
64 (10.5)
36 (5.9)
20 (3.3.)
12 (2.0)
8 (1.3)
9 (1.5)
1 (0.2)
1 (0.2)
1 (0.2)
2 (0.3)
0 (0.0)
0 (0.0)
0 (0.0)

CNS Depressants (M (SD))
1 (n (% of users))
2 (n (% of users))
3 (n (% of users))
4 (n (% of users))
5 (n (% of users))
6 (n (% of users))
7 (n (% of users))
8 (n (% of users))
9 (n (% of users))
10 (n (% of users))
11 (n (% of users))
12 (n (% of users))
13 (n (% of users))
14 (n (% of users))
15 (n (% of users))

3.47 (2.20)
109 (18.9)
115 (19.9)
119 (20.6)
86 (14.9)
55 (9.5)
41 (7.1)
19 (3.3)
19 (3.3)
3 (0.5)
6 (1.0)
3 (0.5)
0 (0.0)
2 (0.3)
1 (0.2)
0 (0.0)

3.45 (2.26)
98 (18.8)
125 (24.0)
92 (17.7)
60 (11.5)
62 (11.9)
26 (5.0)
23 (4.4)
13 (2.5)
17 (3.3)
2 (0.4)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (0.4)

3.49 (2.31)
77 (17.5)
102 (23.1)
90 (20.4)
62 (14.1)
39 (8.8)
28 (6.3)
14 (3.2)
10 (2.3)
6 (1.4)
7 (1.6)
1 (0.2)
3 (0.7)
0 (0.0)
2 (0.5)
0 (0.0)
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Number of Motives Endorsed
Wave 1
Opioids (M (SD))
3.75 (2.46)
1 (n (% of users))
106 (17.4)
2 (n (% of users))
115 (18.9)
3 (n (% of users))
122 (20.0)
4 (n (% of users))
80 (13.1)
5 (n (% of users))
66 (10.8)
6 (n (% of users))
36 (5.9)
7 (n (% of users))
31 (5.1)
8 (n (% of users))
22 (3.6)
9 (n (% of users))
12 (2.0)
10 (n (% of users))
6 (1.0)
11 (n (% of users))
6 (1.0)
12 (n (% of users))
4 (0.7)
13 (n (% of users))
1 (0.2)
14 (n (% of users))
2 (0.3)
15 (n (% of users))
0 (0.0)
16 (n (% of users))
0 (0.0)
17 (n (% of users))
0 (0.0)
Note. All frequencies and percentages are weighted.

Wave 2
3.58 (3.73)
100 (19.7)
95 (18.7)
83 (16.4)
79 (15.6)
50 (9.9)
33 (6.5)
29 (5.7)
14 (2.8)
2 (0.4)
9 (1.8)
5 (1.0)
4 (0.8)
2 (0.4)
0 (0.0)
0 (0.0)
0 (0.0)
2 (0.4)

Wave 3
3.53 (2.54)
80 (21.0)
84 (22.0)
69 (18.1)
44 (11.5)
35 (9.2)
25 (6.6)
15 (3.9)
11 (2.9)
7 (1.8)
3 (0.8)
2 (0.5)
1 (0.3)
2 (0.5)
1 (0.3)
1 (0.3)
1 (0.3)
0 (0.0)

Missing Data Analyses
Since many of the analyses that were run operate under the assumption that the data is
missing completely at random, missing data analyses were conducted. According to Little’s chisquare statistic (Little, 1988) data was missing completely at random (MCAR), χ2 = 12882.59, df
= 16252, p = 1.00. Regardless, as discussed previously, for tests that may be biased based on
missing data patterns, other precautions were implemented. For example, the correlation
structure was specified in the GEE analyses, even though GEE models are more flexible for
missing data compared to other models (Zeger et al., 1988).
Changes in NMUPD Motivations Across Young Adulthood
Table 5 reports the motivations that had significant differences across waves for all
NMPUD users, including the Wald Chi-square statistic and results from the subsequent pairwise
comparisons using Bonferroni corrections. Overall, there were relatively few motives that
evidenced a main effect of time. For stimulants, in general, participants reported less
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experimentation and more motivation to increase energy over time. For CNS depressants,
participants reported more motivation to decrease the effects of other drugs and to relieve
physical pain over time. For opioids, participants reported less experimentation, less boredom,
and more motivation to relieve physical pain as they matured. Additionally, GEE models for the
motivations of addiction for stimulants, and to decrease the effect of other drugs for opioids were
unable to converge, potentially as a result of the small number of participants endorsing these
motives across waves (i.e., 20 and 28; respectively).
Table 5.
Significant changes in NMUPD motivations across young adulthood for all users
NMUPD Motivation

Wald chi-square

Pairwise comparisons

Stimulants
To experiment—to see what it’s like

χ2 (2, N = 792) = 17.08***
χ2 (2, N = 792) = 11.92**

Wave 1 > Wave 3***
Wave 2 > Wave 3**
Wave 1 < Wave 3**

χ2 (2, N = 535) = 8.82*

Wave 1 < Wave 3**

χ2 (2, N = 534) = 6.23*

Wave 1 < Wave 2*

To get more energy
CNS depressants
To decrease (offset) the effects of some
other drug(s)
To relieve physical pain
Opioids
To experiment—to see what it’s like

χ2 (2, N = 559) = 10.86**

Wave 1 > Wave 2*
Wave 1 > Wave 3*
2
**
Because of boredom, nothing else to do χ (2, N = 559) = 10.86
Wave 1 > Wave 2*
To relieve physical pain
χ2 (2, N = 560) = 9.12*
Wave 1 < Wave 3*
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for
the Wald chi-square statistics. * p < .05, ** p < .01, *** p < .001.
Sex as a Moderator in Changes in NMUPD Motivations
Table 6 reports the Wald chi-square statistics for NMUPD motivations that had a main
effect for sex and/or significant moderation (Wave*Sex), along with the frequencies and
percentages of the sex differences observed. For stimulants, significantly more males endorsed
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the following motivations: experimentation, have a good time with friends, increase the effects
of other drugs, decrease the effects of other drugs, and to stay awake. More females endorsed
using stimulants non-medically to lose weight.
For CNS depressants, more males endorsed the following motivations: experimentation,
to feel good/get high, and have a good time with friends. More females endorsed being
motivated to use CNS depressants non-medically to get sleep.
For opioids, more males endorsed the following motivations: experimentation, to feel
good/get high, and to have a good time with friends. More females endorsed using opioids nonmedically to get sleep, relieve physical pain, and to control coughing.
Two motivations were moderated by sex, as indicated by a significant Wave*Sex
interaction. These included to feel good/get high for stimulant medications and to have a good
time with friends for CNS depressants.
Additionally, GEE models for the following motivations were unable to converge or
received an error for concerns about validity: addiction for stimulants, seeking deeper
understanding, fit in with a group, boredom, to decrease the effects of other drugs for CNS
depressants, and fit in with a group, to decrease the effect of other drugs, and as a substitute for
heroin for opioids. Further, for the motivation to get through the day for stimulant medications,
although a significant Wald chi-square was reported for a Wave*Sex moderation (χ2 (2, N = 790)
= 11.40, p = .003), no significant findings were reported in the subsequent pairwise comparisons.
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Table 6.
Frequencies and percentages of users by sex and wave for significant GEE models, Wald chi-square and pairwise comparisons for
main effect of sex and wave*sex
NMUPD Motivation

Wave 1
Male: n (%)
Female: n (%)

Wave 2
Male: n (%)
Female: n (%)

Wave 3
Male: n (%)
Female: n (%)

Wald chi-square for sex

Wald chi-square for Wave*Sex

127 (45.5)
143 (39.4)
110 (39.2)
142 (39.4)

109 (41.1)
96 (30.3)
103 (38.7)
114 (36.0)

57 (32.4)
42 (21.1)
73 (41.9)
57 (28.7)

χ2 (1, N = 790) = 8.94**
Male > Female
ns

ns

88 (31.3)
86 (23.7)
36 (12.8)
25 (6.8)
17 (6.1)
9 (2.6)

79 (29.5)
82 (25.7)
26 (9.8)
15 (4.7)
17 (6.3)
11 (3.4)

59 (33.7)
41 (20.6)
21 (12.0)
12 (5.9)
14 (8.2)
6 (3.0)

χ2 (1, N = 790) = 6.24*
Male > Female
χ2 (1, N = 790) = 12.02**
Male > Female
χ2 (1, N = 790) = 8.75**
Male > Female

190 (71.5)
188 (59.1)
32 (11.9)
149 (47.0)

131 (75.0)
108 (54.9)
19 (10.7)
110 (55.9)

χ2 (1, N = 790) = 25.45***
Male > Female
χ2 (1, N = 790) = 120.58***
Female > Male

ns

To help me lose
weight

193 (68.9)
221 (61.1)
24 (8.6)
180 (49.8)

CNS depressants
To experiment—to see
what it’s like
To feel good or get
high
To have a good time
with my friends

50 (44.6)
63 (31.6)
52 (47.0)
66 (33.1)
29 (26.3)
30 (15.1)

57 (47.9)
36 (21.7)
66 (55.5)
50 (30.4)
43 (36.3)
26 (15.7)

44 (40.2)
32 (20.0)
55 (49.8)
43 (26.6)
28 (25.1)
19 (11.6)

χ2 (1, N = 535) = 27.85***
Male > Female
χ2 (1, N = 535) = 15.56***
Male > Female
χ2 (1, N = 535) = 6.31*
Male > Female

ns

45 (40.7)
100 (49.9)

44 (36.9)
87 (52.3)

54 (48.9)
90 (56.3)

χ2 (1, N = 535) = 5.77**
Female > Male

Stimulants
To experiment—to see
what it’s like
To feel good or get
high
To have a good time
with my friends
To increase the effects
of some other drug(s)
To decrease (offset)
the effects of some other
drug(s)
To stay awake

To get sleep
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χ2 (2, N = 790) = 10.27**
Wave 1 females > Wave 3 females*
Wave 3 males > Wave 3 females*
ns
ns
ns

ns

ns
χ2 (1, N = 535) = 6.69*
Wave 1 females < Wave 2 males*
Wave 2 females < Wave 2 males*
ns

NMUPD Motivation

Wave 1
Male: n (%)
Female: n (%)

Wave 2
Male: n (%)
Female: n (%)

Wave 3
Male: n (%)
Female: n (%)

Opioids
To experiment—to see
what it’s like
To feel good or get
high
To have a good time
with my friends
To get sleep

Wald chi-square for sex

Wald chi-square for Wave*Sex

91 (65.0)
69 (51.1)
45 (44.2)
χ2 (1, N = 557) = 24.75***
ns
75 (41.1)
51 (30.1)
33 (24.1)
Male > Female
89 (63.8)
81 (59.7)
64 (62.3)
χ2 (1, N = 557) = 12.40***
ns
89 (48.7)
64 (38.0)
54 (39.3)
Male > Female
55 (39.0)
46 (34.2)
34 (32.8)
χ2 (1, N = 557) = 11.81***
ns
41 (22.4)
35 (21.0)
23 (16.6)
Male > Female
28 (19.8)
31 (22.6)
25 (24.7)
χ2 (1, N = 557) = 7.70**
ns
64 (34.9)
57 (33.7)
44 (31.8)
Female > Male
To relieve physical
57 (41.1)
68 (49.3)
57 (55.2)
χ2 (1, N = 558) = 8.83**
ns
pain
94 (51.4)
110 (65.3)
100 (72.3)
Female > Male
To control coughing
9 (6.4)
10 (7.3)
7 (6.5)
χ2 (1, N = 558) = 4.68*
ns
22 (11.9)
22 (13.2)
17 (12.3)
Female > Male
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05,
**
p < .01, *** p < .001.
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College Attendance as a Moderator in Changes in NMUPD Motivations
Table 7 reports the Wald chi-square statistics for NMUPD motivations which had a main
effect for college attendance and/or significant moderation (Wave*College Attendance), along
with the frequencies and percentages of the college attendance differences observed. There only
were valid significant findings for NMUPD motivation for stimulant medications. Specifically,
young adults not enrolled in college courses were more likely to endorse the following
motivations: to relax or relive tension, to feel good/get high, have a good time with friends, and
to help lose weight.
GEE models for the following motivations were unable to converge or received an error
for concerns about validity: addiction and to help study for stimulants, seeking deeper
understanding, to have a good time with friends, fit in with a group, to decrease the effects of
other drugs, and addiction for CNS depressants, and to feel good/get high, seeking deeper
understanding, to have a good time with friends, fit in with a group, to get away from problems,
to increase the effects of other drugs, to decrease the effects of other drugs, as a substitute for
heroin, and addiction for opioids. Further, for the motivation, because of anger or frustration, for
opioid medications, although a significant Wald chi-square was reported for a college attendance
main effect (χ2 (1, N = 558) = 3.86, p = .049), no significant findings were reported in the subsequent
pairwise comparisons.
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Table 7.
Frequencies and percentages of users by college attendance and wave for significant GEE models, Wald chi-square and pairwise
comparisons for main effect of college attendance and wave*college attendance
NMUPD Motivation

Wave 1
Not enrolled:
n (%)
Enrolled:
n (%)

Wave 2
Not enrolled:
n (%)
Enrolled:
n (%)

Stimulants
To relax or relieve tension

Wave 3
Not enrolled:
n (%)
Enrolled:
n (%)

Wald chi-square for
college attendance

Wald chi-square for
Wave*College
Attendance

34 (14.0)
30 (10.0)
21 (7.9)
χ2 (1, N = 1013) = 8.21**
ns
38 (9.7)
16 (5.8)
3 (2.5)
Not enrolled > Enrolled
110 (44.7)
141 (47.1)
98 (36.7)
χ2 (1, N = 1013) = 12.18*** ns
To feel good or get high
140 (35.9)
76 (26.9)
33 (30.7)
Not enrolled > Enrolled
74 (30.3)
97 (32.3)
73 (27.6)
χ2 (1, N = 1013) = 4.48*
ns
To have a good time with my
99
(25.3)
63
(22.3)
26
(24.5)
Not
enrolled
>
Enrolled
friends
87 (35.5)
117 (38.8)
98 (37.0)
χ2 (1, N = 1013) = 7.03**
ns
To help me lose weight
116 (29.6)
64 (22.9)
30 (28.3)
Not enrolled > Enrolled
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05,
**
p < .01, *** p < .001.
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Differences in NMUPD Motivations for Youth who Used in High School Compared to New
Users at Wave 1
Table 8 reports the significant results from logistic regression analyses which estimated if
new NMUPD users at Wave 1 (coded “1”) reported different motives than individuals who
reported NMUPD in high school (coded “0”) for each prescription drug class. Participants who
did not endorse NMUPD in high school were more likely to endorse the following motivations:
(1) For stimulants: to feel good/get high, to get through the day, to stay awake, to get more
energy, and to lose weight, (2) for CNS depressants: to feel good/get high, (3) for opioids: to
relax/relieve tension, to feel good/get high, to get away from problems, to get sleep, as a
substitute for heroin, and to relieve physical pain. Effect sizes ranged from small (R2 = .008) to
large (R2 = .075). The motivation most influenced by new NMUPD status at Wave 1 was using
prescription opioids as a substitute for heroin, with participants who reported no non-medical use
of prescription opioids in high school 6.06 times more likely to endorse this motivation
compared to individuals who reported using prescription opioids non-medically in high school.
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Table 8.
Significant logistic regression model results, effect sizes, and odd ratios of NMUPD motivations
for new users at Wave 1 compared to individuals who reported use in high school
NMUPD Motivation

Model Results
Nagelkerke’s R2

OR (95% CI)

Stimulants
To feel good or get high
To get through the day
To stay awake
To get more energy
To help me lose weight

χ2 (1) = 3.98, p = .046, R2 = .008
χ2 (1) = 5.12, p = .024, R2 = .012
χ2 (1) = 5.75, p = .016, R2 = .012
χ2 (1) = 19.73, p < .001, R2 = .042
χ2 (1) = 11.39, p = .001, R2 = .025

1.38 (1.01-1.90)
1.52 (1.06-2.17)
1.50 (1.08-2.09)
2.11 (1.52-2.93)
1.78 (1.27-2.48)

CNS depressants
To feel good or get high

χ2 (1) = 5.05, p = .025, R2 = .022

1.71 (1.07-2.73)

Opioids
To relax or relieve tension
χ2 (1) = 16.99, p < .001, R2 = .068 2.61 (1.64-4.15)
To feel good or get high
χ2 (1) = 4.99, p =.025, R2 = .020
1.68 (1.06-2.66)
2
2
To get away from my problems or
χ (1) = 5.81, p = .016, R = .030
2.10 (1.15-3.83)
troubles
To get sleep
χ2 (1) = 5.75, p = .017, R2 = .025
1.83 (1.12-2.99)
As a substitute for heroin
χ2 (1) = 4.14, p = .042, R2 = .075
6.06 (0.87-41.67)
2
2
To relieve physical pain
χ (1) = 5.42, p = .020, R = .022
1.71 (1.09-2.69)
Note. NMUPD = Non-medical use of prescription drugs. No NMUPD in high school = 1, NMUPD
in high school = 0.
Post hoc analyses for wave 1 NMUPD use comparing young adults who used in high
school and young adults who initiated use in wave 1. To rule out the alternative explanation
that engaging in NMUPD in high school is a protective factor in post hoc analyses were
conducted. Independent t-test analyses were conducted to compare frequency of past year
NMUPD wave 1 use for young adults who used in high school versus young adults who initiated
NMUPD in wave 1. As seen in Table 9, results indicated that there were statistically significant
relations between when young adults initiated NMUPD (in high school versus wave 1) and their
frequency of NMUPD use at wave 1. Specifically, young adults who reported using any class of
prescription drug non-medically in high school were more likely to use any other class of
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prescription drug non-medically at wave 1. Levene’s test for equality of variances was
significant for all analyses and the results presented are the values when equal variances were not
assumed. Effect sizes were in general medium range (Cohen’s d: 0.36-0.70), with the highest
effect sizes in the medium to large range consistently observed for future use of previously used
prescription drug class (e.g., if used stimulants non-medically in high school, most likely to use
stimulants at wave 1 compared to other prescription drug classes).
Table 9.
Independent t-test results for wave 1 NMUPD use across prescription drug classes comparing
youth who initiated NMUPD in high school versus initiated NMUPD in wave 1
NMUPD Frequency

Initiated
NMUPD in
high school
(M (SD))

Initiated
NMUPD in
Wave 1
(M (SD))

t-value

df

NMUPD Stimulant Users
Past year stimulant use
Past year CNS depressant use
Past year opioid use

2.08 (1.79)
1.35 (1.01)
1.33 (0.98)

1.13 (0.67)
1.05 (0.34)
1.06 (0.42)

14.83*** 816.91 0.70
8.21*** 812.56 0.40
7.58*** 821.84 0.36

CNS depressants
Past year stimulant use
Past year CNS depressant use
Past year opioid use

2.00 (1.76)
1.63 (1.27)
1.46 (1.17)

1.17 (0.79)
1.04 (0.34)
1.07 (0.43)

9.91***
9.68***
7.09***

Cohen’s d

461.81 0.60
42.55 0.62
453.87 0.44

Opioids
Past year stimulant use
1.91 (1.68)
1.18 (0.81)
9.19*** 468.55 0.55
Past year CNS depressant use 1.43 (1.10)
1.06 (0.38)
7.13*** 455.66 0.45
Past year opioid use
1.68 (1.34)
1.06 (0.38)
9.75*** 448.46 0.63
Note. NMUPD = Non-medical use of prescription drugs. * p < .05, ** p < .01, *** p < .001.

Changes in NMUPD Motivations Across Young Adulthood for New Users
Table 10 reports the motivations that had significant differences across waves for new
NMUPD users at each wave, including the Wald Chi-square statistic and results from the
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subsequent pairwise comparisons using Bonferroni corrections. Overall, similar to all users, there
were relatively few motivations that evidenced a main effect of time for new NMUPD users.
Similar patterns were observed, including the same significant differences between
waves, for the following motivations of all NMUPD and new NMUPD users by prescription
drug class: (1) For stimulants, the motivation to experiment decreased less over time, and to get
more energy increased over time in general; (2) for CNS depressants, to relieve physical pain
increased over time; (3) for opioids, to experiment decreased over time, and boredom decreased
over time. Further, for opioids a similar pattern of reporting more of the motivation to relieve
physical pain was seen between Wave 1 and Wave 3. However, for new users there was an
additional significant difference between Wave 1 and Wave 2, with increases over time.
Compared to the results for all NMUPD users, new users had different trajectories of the
following motivations. For CNS depressants, there were no significant differences found over
time for the motivation to decrease the effects of other drugs in new users like there was for all
users. Additionally, new users did report a significant increase between Wave 2 and Wave 3 for
the motivation to get through the day.
Additionally, the GEE models for the following motivations were unable to converge or
received an error for concerns about validity: addiction for stimulants, seeking deeper
understanding, boredom, and to decrease the effects of other drugs for CNS depressants, and to
get away from problems, to increase the effects of other drugs, and to decrease the effects of
other drugs for opioids.
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Table 10.
Frequencies, percentages of users, and significant changes in NMUPD motivations across young adulthood for new users
NMUPD Motivation

Wald chi-Square

Pairwise comparisons

164 (42.6) 127 (40.7) 42 (29.9)

χ2 (2, N = 847) = 16.87***

193 (53.4) 163 (52.3) 79 (56.3)

χ2 (2, N = 847) = 12.45**

Wave 1 > Wave 3***
Wave 2 > Wave 3**
Wave 1 < Wave 3**

CNS depressants
To get through the day
To relieve physical pain

9 (4.4)
27 (12.2)

5 (2.8)
53 (28.1)

14 (8.9)
43 (27.8)

χ2 (2, N = 446) = 6.29*
χ2 (2, N = 442) = 6.01*

Wave 2 < Wave 3*
Wave 1 < Wave 2*

Opioids
To experiment—to see what it’s like

105 (43.6) 71 (33.0)

37 (26.2)

χ2 (2, N = 472) = 10.71**

28 (11.5)

13 (9.2)

χ2 (2, N = 472) = 10.66**

Wave 1 > Wave 2*
Wave 1 > Wave 3**
Wave 1 > Wave 2**

Stimulants
To experiment—to see what it’s like
To get more energy

Because of boredom, nothing else to

Wave 1
n (%)

Wave 2
n (%)

Wave 3
n (%)

16 (7.6)

do

χ2 (2, N = 471) = 8.62*

Wave 1 < Wave 2*
Wave 1 < Wave 3*
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05,
**
p < .01, *** p < .001.
To relieve physical pain

84 (35.1)

101 (47.0) 73 (51.4)
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Post Hoc Analyses for NMUPD Motivations
Latent class analyses (LCAs) were conducted in an exploratory fashion as a potential
method of data reduction to provide more information for the motivations that were not able to
be reliably tested with the GEE analyses once moderators were included, likely as a result of
smaller sample sizes once the data were weighted. However, as suggested in the literature and
other similar studies (e.g., McCabe & Cranford, 2012), the low frequency motivations were
removed from the LCAs. Therefore, that data was still not captured. One advantage of LCAs is
that they are considered person-centered, while GEEs are for estimating the population level
information (Homish et al., 2010). One strength of this data set is that it is nationally
representative and there is the potential to look at population-level information. Therefore, it was
decided that investigating the motives individually provided better insight into this phenomena,
rather than grouping them together. The results from the LCAs can be provided by the author
upon request. It should be noted that there were not clear consistent class findings across waves
for all of the prescription drug classes.
Discussion
The present study investigated the developmental changes in NMUPD motivations during
young adulthood (ages 19 to 24; three waves of data) in a nationally representative sample
combining data from 1976 to 2013. Additionally, changes in NMUPD motivations by sex,
college attendance, use in high school, or new user status were researched. NMUPD motivations
were studied across the prescription drug classes of stimulants, CNS depressants, and opioids.
Approximately 4-8% of young adults endorsed NMUPD, which was similar to, or slightly lower
than, other national estimates (e.g., SAMHSA, 2014). Stimulants (e.g., Adderall) were the most
frequently used prescription drug class in the past year across young adulthood. This suggests
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that research and interventions targeting the non-medical use of prescription stimulants continue
to be important endeavors. However, in general, young adults who did endorse NMUPD most
commonly reported infrequent use (1-5 times in the past year). While the reports of infrequent
use call into question how problematic NMUPD is on the national level, the known negative
consequences of NMUPD cannot be ignored (e.g., Arria et al., 2008; Bavarian et al., 2013;
Janusis & Weyandt, 2010; Lo et al., 2013; McCauley et al., 2009; McCauley et al., 2010;
McCauley et al., 2011; Van Eck et al., 2012; Zullig & Divin, 2012). Future work should
thoroughly investigate what are the predictors and mechanisms of problematic NMUPD,
specifically by prescription drug class, to get a better understanding of how frequency of
NMUPD relates to the reported adverse outcomes.
Below, the results are reviewed in terms of the hypotheses and previous research. Areas
of future research in relation to each major finding are discussed. Unique and unexpected
findings are highlighted. Limitations of the current study, emerging research questions, and
general conclusions close the section. Key findings from this study were that both recreational
and self-treatment motivations were commonly reported over time and across drug classes,
suggesting a need for multifaceted treatments. Generally, NMUPD motivations remained
relatively stable across young adulthood. The motivations of experimentation and boredom
decreased for some drug classes, and increased in select self-treatment motivations. Overall, men
were more likely to endorse recreational motivations, while women were more likely to endorse
self-treatment motivations, with some exceptions by prescription drug class. Women also were
more likely to report using prescription stimulants non-medically to lose weight. Young adults
not enrolled in college courses were more likely to endorse using stimulants non-medically for
different reasons than their peers who were enrolled. There also were differences in motivations
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based on if young adults initiated NMUPD in high school compared to when they were 19 to 20
years old. Yet, there were not many differences in NMUPD motivations across young adult
development for new users.
Programs which target the most popularly endorsed NMUPD motivations will likely be
successful in reducing NMUPD across young adult development for new and continued users.
However, to be the most effective, efforts focusing on reducing NMUPD may need to be adapted
by prescription drug class, sex, and college attendance status. Prevention efforts which start in
high school may be useful in reducing NMUPD in the young adult population.
Descriptive Findings and Implications
Certain motivations were popular across the three waves of data for NMUPD and the
majority of young adults endorsed multiple motivations, leveling off around four to five reasons
for engaging in NMUPD. For stimulants the motivations endorsed primarily were educational
enhancement (i.e., to help me study), and the clinical reasons the medications are prescribed, or
self-treatment motivations (i.e., to stay awake, to get more energy). Recreational motivations
(i.e., to feel good or get high, to experiment) and weight loss rounded out the stimulant category.
For CNS depressants, NMUPD motivations focused mainly around self-treatment (i.e., to relax
or relieve tension, to get sleep), recreational motivations (i.e., to feel good or get high, to
experiment), and for the side-effect of pain relief. For the non-medical use of prescription
opioids the commonly reported motivations included recreational (i.e., to feel good to get high,
to experiment) and self-treatment motivations (e.g., to relax or relieve tension, to relieve physical
pain). The results give support to both the self-medication hypothesis and Arnett’s theory on
recreational substance use in emerging adulthood (Arnett, 2005; Duncan,1974a; 1974b; 1975;
Khantzian, 1985; 1997). Given the variety of motivations endorsed for NMUPD, prevention and
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intervention efforts should be multifaceted to address the different motivations. Since, across
prescription drug classes, both self-treatment and recreational motivations were commonly
reported, both need to be included in prevention and intervention efforts. Additionally, there may
be a need to design specific interventions based on each drug class’s inherent properties and
clinically prescribed effects, as well as popular side effects (e.g., weight loss for stimulants and
physical pain relief for CNS depressants).
Interestingly, the percentages of NMUPD users attending college classes decreased over
time for all prescription drug classes. This suggests that young adults who engage in NMUPD
may be at more risk for college drop out. On the other hand, there may be other confounding
factors (e.g., mental or physical health issues, Huang et al., 2006) that makes attending college
classes difficult for this population and NMUPD more likely, and is an area of future research.
This finding complements other work that has found that college students who endorse the nonmedical use of prescription stimulants and opioids spent less time studying, skipped classes more
often, and earned lower grades compared to their non-using peers (Arria et al., 2008). These
factors may explain the observed reduction in college attendance over time. The results from the
present study also suggest that similar risk factors may be relevant for college students who use
CNS depressants non-medically. Additionally, future work need to consider graduation rates
which may also explain the low numbers of college attendance, particularly when the sample is
23 to 24 years old.
Changes in NMUPD Motivations Across Young Adulthood
In terms of the main aims of the study, according to GEE models, motivations to engage
in NMUPD were relatively stable over time. As a result, many of the study’s hypotheses about
overall changes in NMUPD motivations across young adulthood were only partially supported,
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and in general, varied by prescription drug class. The prediction that was most accurate was that
there would be no change over time for following motivations: to seek deeper insights and
understanding, because of anger or frustration, to get through the day, to increase the effects of
some other drug(s), to decrease (offset) the effects of some other drug(s), as a substitute for
heroin, and to control coughing. The only time this hypothesis was not supported was for CNS
depressants, where to decrease the effects of some other drug(s), was found to increase between
wave 1 and wave 3. This finding proposes that CNS depressants may be more likely to be
combined with other drugs, especially as young adults get older. This may be because as young
adults age they become exposed to a greater variety of substances, and therefore they are more
likely to be combing drugs. Indeed in young adult and college student samples, those who
engage in NMUPD were more likely to endorse using other drugs, binge drinking, and
combining their prescription drugs with other substances (Advokat et al., 2008; Barrett et al.,
2005; Garnier et al., 2009; McCabe et al., 2007; McCabe et al., 2009; McCabe et al., 2006;
SAMHSA, 2006). These behaviors increase the risk of potentially dangerous drug interactions
and their negative outcomes. Specifically with CNS depressants, the disinhibitory and aggressive
effects that result in violence and assault, as well as the risk for opioid-related deaths, are
increased when CNS depressants are combined with alcohol and other drugs (Jann et al., 2014;
Lader, 2011; Webster et al., 2011). Additionally, as this suggests that young adults are using a
variety of drugs, treatment programs may not be effective if they are only targeting NMUPD.
More research needs to be conducted in understanding how NMUPD fits into the larger drug
culture, and how and why using CNS depressants to regulate the effects of other drugs increases
overtime, while the use of stimulants and opioids to regulate the effects of other drugs remain
more stable.
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It was predicted that for recreational motivations, like to feel good or get high, for
experimentation, and boredom, would decrease over time across all prescription drugs classes as
young adults move towards more stability based on Arnett’s theory of emerging adulthood
(Arnett, 2005). This hypothesis also was partially supported. The NMUPD motivation of
experimentation decreased across young adulthood for stimulant and opioid medications.
Additionally, the NMUPD boredom motivation decreased between wave 1 and wave 2 for opioid
medications, and was stable between waves 2 and 3. These findings support Arnett’s theory that
as young adults age they are less likely to use substances for recreational reasons as part of the
self-exploration process and instability experienced during this this developmental period
decreases. As a result, targeting these more recreational motivations may be more appropriate
when individuals are entering young adulthood; at least for stimulant and opioid medications.
On the other hand, using prescription drugs non-medically to feel good or get high was
consistent over time and a popularly endorsed motivation across prescription drug classes (i.e.,
reported by 35-55% of users). This should remain a target of intervention across young
adulthood. The popularity and consistency of this motivation calls into question parts of Arnett’s
theory (2005) which would suggest that young adults would engage less in NMUPD to feel good
or get high as they become more stable and potentially experience less stress and optimism.
Additionally, according to research on brain development around this age, young adults should
have the cognitive capacity to make methodical decisions over emotion-driven decisions (e.g.,
Steinberg, 2008), which would decrease this emotionally related motivation. Therefore, more
work needs to be conducted to see if by age 24 young adults are actually experiencing less stress
and negative affect associated with disruptions in life as proposed (e.g., new romantic partners,
educational and vocational settings). Since much research has found that many young adults feel
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like they are reaching “adulthood” later and later as traditional markers of adulthood are being
continually delayed (e.g., getting married, buying a house, bearing children; Hutchison, 2015),
this motivation may not actually decrease until later than the age range investigated in this study
(e.g., 30 years old, Arnett, 2000). This could be tested using later cohorts from the MTF study as
more data becomes available in later follow-up waves.
It was also predicted that “self-treatment” motivations (e.g., using the medications as they
are clinically intended) and addiction motivations would increase over time across all
prescription drug classes as exposure to prescription drugs and the risk for psychiatric problems
increases (e.g., Kessler et al., 2005), under the self-medication hypothesis (Duncan, 1974a;
1974b; 1975; Khantzian, 1985; 1997). Again this hypothesis was partially supported in all
prescription drug classes. For stimulants, to get more energy was endorsed more in wave 3
compared to wave 1. In reference to CNS depressants and opioids, to relieve physical pain
increased over time (between wave 1 and wave 2 for CNS depressants, and wave 1 and wave 3
for opioids). This suggests that more outreach may be needed as young adults age to counter
these motivations. Also, prevention may be possible in early young adulthood by using evidencebased treatments to target these motivations. For example, introducing and promoting ways to
increase energy through the use of exercise (Haskell et al., 2007), or to decrease physical pain
through the use of evidence based treatments (e.g., Garg, Joshi, Mishra, & Bhatnagar, 2012),
may help to prevent young adults from engaging in NMUPD. Future research on how to continue
to target these motivations in ways that have less potentially dangerous and harmful effects
compared to NMUPD, are user-friendly, and accessible to young adults continues to be
important.
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However, other self-treatment motivations (i.e., stimulants: to stay awake, to help study,
and to lose weight; CNS depressants: to relax or relieve tension and to get sleep; and opioids: to
relax or relieve tension, and to get sleep) were stable across the three waves of data collection.
This is not to say that these motivations are not important treatment targets, as many are
commonly reported as motivations by this population. Rather, because these self-treatment
motivations remain stable over time targeting them throughout young adulthood is vital.
Again, making alternative methods of treatments available beyond NMUPD is necessary.
Connecting young adults to mental health professionals who can accurately diagnose and
prescribe appropriate treatments, including medications, may help to alleviate these symptoms
while reducing the risks associated with NMUPD, including the potential negative interactions of
ingesting different substances when not being followed by a medical professional (McCabe et
al., 2009). This is especially important as young adults may also misdiagnose their symptoms,
resulting in use of inappropriate medications which in turn may lead to making their underlying
problem worse, not better (Holloway & Bennett, 2012).
Moreover, using prescription CNS depressants and opioids medications as a sleep aid
was endorsed as a relatively common motivation, and to get more energy and to stay awake was
noted as a common motivation for stimulants. Given that the effects of taking medications to
reduce sleep problems have been shown to decline in effectiveness over time and there is
increasing research that supports such protocols as cognitive-behavior therapy as evidence-based
treatments for disorders like insomnia (Morin, 2010), assessing and targeting sleep problems
may be an effective prevention and intervention tool for reducing NMUPD in young adults.
Additionally, as there is evidence that young adults who use prescription stimulants nonmedically report worse subjective and overall sleep quality, as well as more sleep disturbances
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compared to their peers who do not endorse non-medical use of stimulants (Clegg-Kraynok et
al., 2011). As a result, targeting sleep problems may be beneficial to all young adults nonmedically using prescriptions, regardless of prescription drug class.
Further, the addiction motivation did not vary across young adult development. One
reason for this finding may be the low percentage of participants who endorsed addiction as a
motivation, especially for stimulant medications (endorsement ranged from 1.1% to 9.5% of
users). The number of young adults reporting addiction as a motivation for the non-medical use
of prescription stimulants was so low the GEE model was unable to converge. There are a few
potential reasons for why the addiction motivation was endorsed at such a low level across
prescription drug classes. One may be that certain prescription medications have less addictive
properties. In particular, stimulants medications are known to be less addictive as compared to
opioids and CNS depressants (e.g., NIDA, 2011). Alternatively, individuals in this population
may lack insight into their motivations and the potential that they are addicted to these
medications, or are responding in a socially desirable manner. However, given that most of the
sample reported infrequent use, another conclusion could be that not many individuals are
addicted to the medications investigated. This also may explain the low numbers of young adults
seeking treatment (e.g., 3.5% to 10.3%; McCabe et al., 2009), although more have been seeking
treatment over time (e.g., SAMHSA, 2011). The results from this study suggest that targeting
addiction as a motivation for use may not be as effective as targeting other motivations for use.
Further, other treatment models that tend to focus on the addictive qualities of substances (e.g.,
many twelve-step programs, Arria & DuPont, 2010) may not be as appropriate for this
population of substance users. Research needs to investigate though whether young adults
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endorsing recreational motives report improved outcomes from receiving such treatments (Arria
& DuPont, 2010).
Sex Effects on NMUPD Motivations in Young Adults
This study also investigated the role of sex in NMUPD motivations and if sex moderated
the changes in NMUPD motivations across young adulthood using GEE models. It should be
noted, that some of motivations were unable to investigated in this sample as the GEE models
were unable to converge or received an error for concerns about validity. In general, the
hypothesis that more males would endorse recreational motivations compared to females was
supported. Specifically, significantly more males endorsed recreational motivations for
stimulants (i.e., experimentation, have a good time with friends, increase the effects of other
drugs, decrease the effects of other drugs). Males also were more likely than females to be
motivated to use prescription stimulants non-medically stay awake. Similarly, for CNS
depressants and opioids, more males endorsed the following recreational motivations:
experimentation, to feel good/get high, and have a good time with friends. These findings are
similar to previous work that found that males were more likely to endorse recreational and
mixed motivations (both recreational and self-treatment motivations) compared to females in
varied samples of higher education students (Lord et al., 2011; Lord et al., 2009; McCabe et al.,
2007; McCabe et al., 2009). These findings support the generalization of this sex difference to
the larger young adult population.
Conversely, as generally predicted, more females reported self-treatment motivations, or
using the medications as they are clinically intended, compared to males for CNS depressants
and opioids, similar to previous work (Lord et al., 2011; McCabe et al., 2007; McCabe et al.,
2009). More females endorsed being motivated to use CNS depressants and opioids non-
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medically to get sleep as well. Further, more females endorsed using opioids non-medically as
well to relieve physical pain and to control coughing. For stimulant medications, females did not
report more self-treatment motivations, which also was found in one other study (McCabe et al.,
2009). Again, the sex differences found in smaller samples of young adult students appears to
hold true for the greater young adult population.
As a result, it is advisable that prevention and intervention efforts may be more effective
if they are sex-specific. Programs for males could focus more on recreational motivations, while
programs for females could focus on more self-treatment motivations. Efforts to reduce NMUPD
in males should emphasize other methods to engage in recreational activities or promote positive
risk-taking experiences that have less negative consequences associated with them (e.g.,
recreational sports leagues). Research on the effectiveness of these alternative approaches needs
to be explored further. Focus groups including males who do and do not engage in NMUPD may
help researchers and practitioners discover some of the different methods used in these
populations to achieve the same recreational goals. On the other hand, programs for females may
include more evidence-based approaches for sleep and pain improvement as previously
discussed. Additionally, connecting females to mental health professionals to target the
underlying symptoms may be more appropriate.
Moreover, more females endorsed using stimulants non-medically to lose weight. This
contradicts previous work on this topic which found similar reports of using stimulants nonmedically for weight loss purposes (Jeffers et al., 2013; Jeffers & Benotsch, 2014). However,
this research was conducted at one university, which may limit the studies’ findings. The results
from this nationally representative sample highlights that this finding may not be true for the
broader young adult population. This result is not surprising though, given that in the general
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population, young adult females tend to report more concerns about weight loss, using multiple
methods to achieve weight loss, and are diagnosed with more eating disorders (Wilson, Grilo, &
Vitousek, 2007). Given that weight loss was reported by 31% to 35% of non-medical stimulant
users this is a significant motivation to include in prevention and intervention efforts, specifically
treatment groups that are aimed at treated young adult female populations. Programs that have
been found to be effective in making healthy lifestyle changes in young adults, specifically with
weight loss as an outcome (e.g., Anderson, Konz, Frederich, & Wood, 2001), could be effective
in this population to reduce using prescription stimulants non-medically for weight loss reasons.
There were two motivations where sex moderated the changes in NMUPD motivations
over time: to feel good/get high for stimulant medications and to have a good time with friends
for CNS depressants. In particular, females in wave 3 (ages 23/24) were less likely to report the
motivation to feel good/get high for the non-medical use of stimulants compared to females in
wave 1 (ages 19/20) and males in wave 3. Furthermore, males in wave 2 (ages 21/22) were more
likely to endorse the motivation to have a good time with friends for CNS depressant nonmedical use compared to both wave 1 and wave 2 females. Even though protections against Type
I errors were implemented, given the paucity of moderation findings it is possible that these
results are more likely the consequence of chance, and should not be emphasized. However, as
these select findings highlight more recreational motivations, they are in line with previous work
that as young adults age they may become more mature and engage in NMUPD less frequently
for recreational reasons (Arnett, 2005). Further, these results support research on sex differences
on risk-taking behaviors in adolescence and young adulthood where females have been found to
mature more quickly in their decision making processes as compared to males (e.g., Harris,
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Jenkins, & Glaser, 2006). Future studies need to replicate these results before heavily weighing
the implications.
College Attendance Effects on NMUPD Motivations in Young Adults
Differences in young adults’ NMUPD motivations based on college attendance were
researched as well using GEE models. Results from the CNS depressant and opioid prescription
drug classes supported the hypothesis that that college attendance would not moderate the
relations of change in motives over time because young adults in and out of college both
experience the same developmental life stage and associated changes, which provides support for
general theories on young adult development (Arnett, 2005). However, there were general
differences in NMUPD motivations for young adults in regards to the non-medical use of
prescription stimulants, though no moderation was found. The one study that included a
significant sample of young adults both enrolled and not enrolled in college classes found that, in
general, the sample reported using stimulants non-medically both as the medications were
intended and for recreational purposes, similar to studies of solely college students (Upadhyaya
et al., 2010). However, this study did not specifically examine differences in NMUPD
motivations by college attendance. The present study found that young adults not enrolled in
college courses were more likely to endorse using stimulants non-medically to relax or relive
tension, to feel good/get high, have a good time with friends, and to help lose weight. Notably,
none of the motivations reported more by young adults not enrolled in college courses were
using the medications as they are clinically intended. This highlights that young adults not in
college may be at higher risk for using stimulants non-medically for unique reasons and
alternative ways to directly address these motivations may be needed. Future research needs to
continue to include young adults not in college to verify these findings. Also, since a variety of
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motivations were unable to be reliably run, research needs to look more closely at some of the
less reported motivations and in CNS depressant and opioid prescription drug classes.
High School NMUPD Users Have Different Motivations and Risk Factors
To gain a better understanding changes in motivations during the early young adulthood,
logistic regression analyses revealed that young adults who started NMUPD at wave 1 (ages
19/20), compared to those who started NMUPD in high school, were more likely to endorse the
following motivations: (1) For stimulants: to feel good/get high, to get through the day, to stay
awake, to get more energy, and to lose weight, (2) for CNS depressants: to feel good/get high,
and (3) for opioids: to relax/relieve tension, to feel good/get high, to get away from problems, to
get sleep, as a substitute for heroin, and to relieve physical pain. Consequently, young adults who
engage in NMUPD for the first time when they are 19 to 20 years old appear to be motivated by
different factors compared to young adults who had previous NMUPD exposure in high school.
Both recreational and self-treatment motivations were noted in different prescription drug classes
and therefore, these results only partially supported the hypothesis that young adults who initiate
NMUPD shortly after high school would be more likely to endorse recreational motivations.
In reference to the differences in recreational motivations that were found, it is possible
that there is less novelty for individuals who engage in NMUPD at earlier ages. Specifically, the
recreational motivation to feel good/get high was more likely to be reported by new wave 1 users
across all prescription drug classes and highlights an important commonality. One reason this
motivation may be more prevalent in new users is that young adults who reported NMUPD in
high school may be experiencing some tolerance effects (e.g., Rosenfield et al., 2011). Since to
feel good/get high is so widespread, prevention interventions for 19 to 20 year olds that target
this motivation will likely be effective across prescription drug classes.
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Other motivations that were reported more by new wave 1 users suggest that selftreatment needs may be higher in this population compared to young adults who used in high
school. As young adulthood is when many mental health illnesses emerge (Kessler et al., 2005),
it is not surprising that self-treatment motivations are more popular. This may also imply that
those who use NMUPD in high school may have different symptom profiles and needs compared
to individuals who start NMUPD later. This needs to be further investigated by future
researchers. Regardless of whether young adults are treating actual symptoms, the theme of selftreatment suggests that young adults are not receiving the proper medical and mental health
treatment needed. This may be occurring for a variety of reasons including stigma around
receiving treatment, previous negative treatment experiences, limited access to health care,
and/or a lack of awareness that NMUPD is a problem (Lord et al., 2011). Additionally, young
adults may not have the resources to cope with stressors in more adaptive ways. Fostering
support systems, like study or treatment groups, and suggesting adaptive coping strategies like
proper diet and exercise, may help young adults better manage their stress (Herman et al., 2011).
All of these potential problems could be addressed with prevention and intervention strategies,
and may be needed more as individuals transition from adolescence to young adulthood. Future
research should not only assess why there is a treatment gap, but funding should be provided for
studies investigating the effectiveness of targeting these different barriers to treatment.
Interestingly, the motivation most influenced by new NMUPD at wave 1 was using
prescription opioids as a substitute for heroin, with participants who reported no non-medical use
of prescription opioids in high school 6.06 times more likely to endorse this motivation
compared to individuals who reported using prescription opioids non-medically in high school.
One explanation for this may be that these individuals were first using heroin in high school and
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then initiated prescription opioid use in early adulthood. Although, much of the research to date
suggests the opposite relation, that individuals who inject heroin are more likely to report the
misuse of prescription opioids first (Brands, Blake, Sproule, Gourlay, & Busto, 2004; Cicero,
Ellis, Surratt, & Kurtz, 2014; Cicero, Ellis, & Surratt, 2012; Grau et al., 2007; Lankenau et al.,
2012; Peavy et al., 2012; Pollini et al., 2011); this highlights the need for work to also research
the alternative direction. At least one investigation, where the authors pooled data from the
National Survey on Drug Use and Health, did research the alternative hypothesis. While
individuals who used heroin before using prescription opioids non-medically were at an
increased risk for NMUPD, the risk was much greater in the opposite direction, from the nonmedical use of prescription opioids to heroin (2 times more likely versus 19 times more likely,
respectively; Muhuri, Gfroerer, & Davies, 2013). However, these findings highlight that
reducing heroin use may consequently also lead to a reduction in the non-medical use of
prescription opioids. This may be particularly salient for adolescents who use heroin in high
school. However, the timing of use of heroin versus prescription opioids is not completely clear
in this study, as the use is surveyed in the past year. More research on the specific timing and
interplay of these two illicit substances needs to occur.
It is important to recognize that NMUPD in high school was a risk factor for further
NMUPD in the following two years, based on frequency data. Post hoc analyses revealed that
those individuals who reported NMUPD for any prescription drug class in high school were
more likely to endorse NMUPD across all prescription drug classes at wave 1. Importantly, if a
participant used a particular class of prescription drugs in high school, the strongest effects were
for future use of that drug class (e.g., if used stimulants in high school had stronger effect sizes
for future stimulant use compared to other drug classes). This suggests that targeting NMUPD in
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high school could prevent increased use of NMUPD in early young adulthood, even if rates of
NMUPD are lower during adolescence (SAMHSA, 2013b). Further, it does not appear that the
interventions need to target any one specific prescription drug class. Instead, targeting one or all
of the drug classes studied would probably reduce the risk of NMUPD across the board.
Motivations to Initiate Use Similar to Motivations of General Use Across Young Adulthood
Finally, what motivates young adults to initiate NMUPD across young adult development
was studied using GEE models. In general, similar to all users, there were relatively few
motivations that changed over time for new NMUPD users. Additionally, motivations that did
change most often reflected the changes observed in all users. This supports the hypothesis that,
overall, young adults experience the same changes in motivations over time because they are all
experiencing the same developmental life stage and associated changes, which support Arnett’s
(2005) theory. A few differences in motivations were found between all users and new users, but
these were sparse and there were none for the non-medical use of prescription stimulants.
Specifically, for new non-medical users of prescription opioids along with increases in the
motivation to relieve physical pain between wave 1 and wave 3, new users also reported an
increase between wave 1 and wave 2. For CNS depressants, there were no significant differences
found over time for the motivation to decrease the effects of other drugs in new users like there
was for all users. Additionally, new users did report a significant increase between wave 2 and
wave 3 for the motivation to get through the day. While these findings highlight areas for
potential future research, the findings need to be interpreted with caution before they are
replicated. Since two of the findings found more significant differences between more waves,
and in the previously observed direction, this could mean that new users report these motivations
on a sharper slope. In other words, new users may feel the need to relieve physical pain by using

80

prescription opioids or to get through the day by using CNS depressants more frequently than all
users. New users may also be at less risk for combining CNS depressants with other drugs. This
may be because new users are less experienced with drugs in general and are therefore less likely
to be combining substances.
Limitations and Future Research
As with all research, this study has limitations that need to be acknowledged and ideally
addressed in future work. First, this study was secondary data analysis of a reduced data set
which limited the types of questions and confounding variables that could be assessed. Future
work needs to consider other factors that may influence NMUPD motivations in this population
including other demographic factors (e.g., geographic location, GPA, race/ethnicity, etc.) and
other known risk factors for drug use (e.g., stress, trauma, other drug use, etc.). Second, the
current study only assessed frequency of NMUPD and does not include measures of problematic
NMUPD. Since most of the sample reported infrequent use, investigating measures of
problematic use will likely lead to more bountiful information on which motivations may be
most appropriate to target to make the most impact. Additionally, even with a large data set
NMUPD frequency were low once the data were weighted, and consequently so were some of
the reported motivations for use, resulting in difficulties for gaining a thorough understanding of
the less frequently endorsed motivations. However, more research needs to be conducted about
the importance of motivations that are less frequently reported. Spending energy and resources
on these motivations may not be as useful on a larger scale compared to focusing on NMUPD
motivations that are more common in young adulthood. Future work using factor analyses or
other methods of data reduction may be helpful in determining how these motivations may group
together in a clinically relevant way. To increase the sample size for this study multiple cohorts
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were combined from 1976 to 2013, but cohort effects were not assessed as part of this work.
Given the changes in NMUPD frequency (e.g., Lipari et al., 2015) and the increasing availability
of prescription drugs overtime (Yu, 2012), research needs to look at how that may influence this
study’s findings. This study also relied on self-reports which are subject to social desirability and
call into question the accuracy of participants’ reports of negative behaviors, like drug use
(Kazdin, 2003). Some studies that have not looked at motives have used unique methods in
assessing NMUPD including testing campus wastewater for evidence of stimulant medication
use in college populations (Burgard, Fuller, Becker, Ferrell, & Dinglasan-Panlilio, 2013). These
innovative and other more traditional approaches, like using other reporters, should be
considered in future work. This research leaves some other emerging questions unanswered.
These include: How different is NMUPD from other drug use? Are current treatments targeting
these motivations and do they work; specifically for young adults? Are there cultural similarities
and differences in NMUPD motivations across countries? Researchers and advocates for the
prevention of NMUPD in young adults should address these emerging areas while considering
the current findings and concerns of prior research.
Conclusion
Even with these limitations acknowledged, the current study had several strengths
including being the first work to investigate the changes in NMUPD across young adulthood in a
nationally representative sample. Results from this study need to be replicated, but can be
generalized to the American young adult population. As NMUPD motivations were generally
stable over time the best approach to targeting NMUPD based on motivations will be to address
the motivations endorsed the most frequently over time. However, since endorsing more than
motivation was common, these interventions need to be multifaceted. Prevention and
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intervention programs may need to be specialized by sex, and should start in high school to
prevent future use. Young adults both enrolled and unenrolled in college classes need to be
targeted, but those not enrolled in college classes may have different motivation patterns, at least
in terms of stimulant medications. Programs should address these differences and be tested for
their effectiveness.
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